Benefits of Insoles with Real-Time Alert and Foot Self-Care Education in Improving Offloading and Adherence to Prescribed Footwear in Patients with Diabetes Mellitus: Study Protocol for a Single-Blinded Randomized Clinical Trial

Benefits of Insoles with Real-Time Alert and Foot Self-Care Education in Improving Offloading and Adherence to Prescribed Footwear in Patients with Diabetes Mellitus: Study Protocol for a Single-Blinded Randomized Clinical Trial | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Research Article Benefits of Insoles with Real-Time Alert and Foot Self-Care Education in Improving Offloading and Adherence to Prescribed Footwear in Patients with Diabetes Mellitus: Study Protocol for a Single-Blinded Randomized Clinical Trial Ngozi D. Mbue, Wanyi Wang, Bijan Najafi This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-1099111/v1 This work is licensed under a CC BY 4.0 License Status: Posted Version 1 posted You are reading this latest preprint version Abstract Background Unprotected plantar pressure contributes to the development of diabetic foot ulcers (DFU) in people with diabetes and loss of plantar sensation. Recently, smart footwear device is proposed to empower patients at risk in avoiding harmful weight-bearing physical activities such as prolonged standing which may lead to local plantar ischemia and ultimately a DFU. However, there is little progress in the education of at-risk to be engaged in daily using of these smart footwear devices as well as adherence to diabetic footwear. The aim of this study is to examine whether an integration of smart insoles with an alert (smart watch) and foot self-care education may sustain adherence to prescribed footwear and change patients’ behavior to avoid harmful physical activities such as prolonged standing posture. Methods/design : The trial is designed as a three-arm randomized controlled intervention study. Adults with peripheral neuropathy will be recruited. Seventy-two participants will be randomized into three groups: 1) smart insoles + foot self-care education; 2) smart insoles; and 3) usual-care controls with no smart insoles or education. Primary outcomes will be adherence to diabetic footwear and offloading after 6 months. Secondary outcomes are foot self-care knowledge and self-efficacy, reduction of sustained plantar pressure, incident of DFU, acceptability, and perception of benefits of intervention. Data collection will be obtained at baseline, bi-weekly in first month, two, four and six months. Latent growth curve mediation model will be used to test the effects of the combined smart insole and foot self-care education on improving adherence to footwear at every two months until six months, in which time points will be used as repeated measures. It allows for testing differences between groups in patterns over time as well as at specific time points. The Institutional Review Board at the Texas Woman’s University (Reference No. has approved the study protocol FY2021-344). Discussion This clinical trial will provide information on the importance of foot self-care education and the use of technology (smart insole plus smart watch) in reducing the incidence of foot ulcers and increase adherence to diabetic footwear. This research could also lead to critical mechanistic discoveries and, subsequently, major advancements in prevention of DFU and limb amputation. This impact would have high potential for translation to routine clinical diabetes care. Trial registration : United States Clinical Trial Registry NCT05074849. Registered on 29 September 2021. Diabetic footwear Diabetic foot ulcers Adherence Foot self-care education Randomized control trial Figures Figure 1 Figure 2 Figure 3 Background And Rationale Diabetic foot ulcers (DFU) are a major complication of diabetes mellitus, with high morbidity, mortality, and resource utilization [13, 15-18]. On average, annual cost of a DFU is $ 8659 per individual [19], whereas the total medical cost for treatment of diabetic foot diseases in America ranged from $ 9 to $ 17 billion in 2013, an additional cost associated with diabetes management [18, 20, 21]. With the increasing number of aging individuals and individuals with diabetes in the United States every year, a high number of patients with diabetes are at risk for DFU. DFU is largely preventable, yet common in those with diabetes, with an estimated 19–34% risk [3]. More than half of DFUs become infected [3, 26], with approximately 20% of diabetic foot infections leading to amputation [3, 27, 28]. Mortality after diabetes- related amputation exceeds 70% at 5 years for all patients with diabetes [3]. The societal burden of DFU exceeds that of most other health concerns and contributes to the strain on the US healthcare system [21, 29]. A report that examined over 1 million cases of DFUs seen in US emergency departments (ED) from 2006 to 2010 showed a national cost of $ 1. 9 billion per year for ED-related treatments of DFUs alone and $ 8.78 billion per year for inpatient care for these patients [14]. Even when patients receive state-of-the-art preventive care, 12-month recurrence of DFUs exceeds 40% [3]. Sustained adherence to prescribed footwear as well as offloading harmful plantar areas is essential in those with diabetes and at risk for DFU. DFUs can result from multiple factors. One of the most significant factors is elevated plantar pressures in a neuropathic insensate foot [22, 14, 23], often a challenge to manage due to poor circulation associated with a neuropathic limb [2, 23]. Another significant factor is repetitive stress on the foot, particularly in the presence of neuropathy or peripheral artery disease [21]. Presently, these sustained high plantar pressures are managed through passive methods, such as orthotics, medical arch support, Rocker shoes, and custom insoles, which are not effective in reducing pressure in certain areas of the foot [14, 24]. Due to the passivity of these devices, users are limited to physically altering their behavior by offloading harmful pressure areas [14]. The ineffectiveness of the current medical approaches leads to approximately 73,000 amputations every year in the United States, with each amputation costing on average, $ 70,434 in 2010 [25]. Research shows that offloading harmful plantar pressures is a recommended approach [6, 7], as well as adherence to the recommended diabetic footwear. Both approaches have potential to decrease incidence of DFU and ulcer reoccurrence in those with diabetes and at risk for DFU. Progress has occurred in educating those with diabetes and at risk for diabetes foot ulcer about the importance of offloading painful plantar areas, diabetic footwear, and the prevention of foot ulcers [12]. However, limited progress is made in educating individuals about offloading and adherence to diabetic footwear. Data shows that education alone is insufficient in reducing the occurrence of first time and recurrent DFU or adherence to prescribed footwear [13]. Smart insoles with alert technology (smart watch) along with foot self-care education will offer a round -the- clock, patient-specific education, active response, and adherence to prescribed diabetic footwear and will ultimately reduce the incidence of DFUs. Offloading harmful plantar areas and adherence to diabetic footwear and the prevention of foot ulcers in patients with diabetes will require an integrated approach of patient education on foot self-care and wearing therapeutic insoles or prescribed footwear [3]. Adherence to a treatment regime is confirmed to play a key role in clinical outcomes [3, 13, 30]. Interventions targeting those with diabetes and at risk for DFUs are urgently needed to help clinicians treating patients with diabetes. Previous integrated approaches do not involve state-of-the-art interventions or specific knowledge about factors that increase sustained adherence to footwear, prevention, or prediction of DFU recurrence [3]. Our proposed study is an integrated approach that will not only address ways to improve offloading harmful plantar areas and sustained adherence to footwear, but also potentially prevent initial appearance and recurrence of foot ulcers [3]. Objectives The overall purpose of this research is to establish a novel approach to promote adherence to prescribed diabetic footwear and offload harmful plantar areas in individuals with diabetes as well as high incidence of DFU. Our research hypotheses are as follows: (1) Participants with smart insole with real-time alert and foot self-care education will be more adherent to footwear and offloading over 6 months, compared to participants with smart insoles only or usual care. (2) Participants with smart insole with real-time alert and foot self-care education will have higher acceptability and perception of the benefits of their intervention, compared to those randomized to the smart insoles only or usual-care control groups. (3) Changes in adherence will be mediated by self-efficacy and perception of benefits. (4) Participants randomized to the smart insole with real-time alert + foot self-care education will have low incidence of DFUs compared to participants randomized to the smart insoles and usual-care groups. Methods/design Trial design The study was designed as a prospective single-blinded parallel control trial and will follow the principles of the Consolidated Standards of Reporting Trials (CONSORT). The study protocol was written in accordance with the Standard Protocol Items. Recommendations for Interventional Trails (SPIRIT) guidelines. Figure (Fig.) 1 is a sample of high-sustained pressure and alerting screens. The flowchart of the study design is shown in Fig. 2 and a detailed schedule of enrollment, intervention and assessment is given in Fig. 3. The trial is registered in the United States Clinical-trial.gov (NCTT05074849) on 29 September 2021. This is a sample of high-sustained pressure alerting screens from the SurroSense RX smartwatch (Orpyx Medical Technologies Inc., Calgary, Canada). This sustained pressure could be because of the presence of a foreign object inside shoes that may remain unnoticed because of loss of protective plantar sensation in people with diabetes and neuropathy. When an alert is triggered, the user receives auditory, vibratory, and visual feedback from the watch. When the user acknowledges the alert, a map of each connected insoles is shown with the area of high-pressure alert identified in red [14]. Study site Study sites include Baylor College of Medicine (BCM), Michael E. DeBakey VA Medical Center (MEDVAMC) and Texas Woman’s University (TWU) respectively. Many of our adult diabetic patients are seen at our various clinics (i.e., Endocrine and Primary Care at MEDVAMC and Division of Vascular and Endovascular Therapy and Interdisciplinary Consortium on Advanced Motion Performance (iCAMP) at BCM. Michael E. DeBakey Department of Surgery and BCM are the primary sites for recruitment. BCM is a unique environment for innovation. Researchers collaborate across institutions, creating a vast biomedical research ecosystem [44], building on over a century of leadership in biomedical research. Participants The proposed study will recruit 72 patients, men and women, 18 years and above, ambulatory and have prescribed diabetic shoes seen in the clinics and centers around Houston, Texas. Individuals will be eligible for the trial if they meet the following inclusion criteria: (1) History of diabetes peripheral neuropathy (DFN) with and without history of peripheral artery disease (PAD); (2) history of foot ulcers within the last 6 months; (3) willing and able to attend follow up visits such as long distance (i.e., greater than 30 miles to recruitment sites); (4) able to read and follow directions; and (5) those going through hemodialysis. However, individuals will not be enrolled into this trial if they meet the following exclusion criteria: (1) Active Charcot Arthropathy or major foot deformity; (2) wide spread malignancy or systemically immunocompromising disease; (3) gangrene, active infection; (4) major amputation (above ankle); (5) Mini Mental Status-Examination (MMSE<20); (6) unable to keep research appointments; (7) unable to walk safely a distance of 100 feet with or without walking assistance; (8) cardiopulmonary disease (e.g., recent MI, Stroke); (9) significant lower extremity edema which may limit the participant from fitting into standard diabetic foot wear;(10) refusal to wear prescribed diabetic footwear; (11) those with alcohol and drug abuse over the last 6 months; and (12) severe orthopedic and/or neuromuscular impairments. Individuals interested in the study will undergo a telephone interview by a member of the research team. Those meeting the preliminary inclusion criteria will be invited to discuss their potential participation in details. During the screening visit, detailed information will be provided to study participants. Verbal and written information of potential benefits and risks of the study will be provided; their questions and concerns will be addressed. Written informed consent will be obtained by a trained researcher at the baseline visit. On the consent form, participants will be asked whether they agree to use their data when they withdraw from the trial and ask for permission for the research team to share their de-identify data with people from both universities taking part in the research or from the regulatory authorities. Sample size calculation This is a randomized control trial (RCT) study. The 63 participants will provide basic descriptive information on the various outcomes in the study (e.g., increased adherence to footwear, increased offloading, and decreased foot ulcers and improved foot self-care knowledge,). Sample size was estimated based on an initial study using a smart insole, conducted by Najafi et al. (Co- Investigator) [14]. In their study, the researchers observed that, in the group with at least one alert every 2 hours (high-alert group), adherence to footwear was improved and became significantly higher than in the low-alert group after 3 months of daily use of the technology (adherence to the prescribed footwear: 8.0±3.7 hours in the high-alert group v. 3.6±1.8 hours in the low-alert group, p = 0.035, Cohen’s effect size d = 1.37) indicating very large effect size. A priori power analysis was conducted using Optimal Design 3.01. Based on a desired level of power set at 0.80, an alpha level of 0.05, and a more conservative large, standardized effect size of d = 0.80, a minimum sample size of 63 is required for the 3 repeated measures on the primary outcome adherence to observe a significant difference between groups over time. With consideration of 10% drop out rate and the even sample size distribution among the 3 groups, a total of 72 (24 per group) are needed at the beginning of the study. Randomization and blinding Participants (72 participants) meeting the inclusion and exclusion criteria will be randomized (24 per group) into 3 groups: 1) smart insoles + foot self-care education (Group 1); 2) smart insoles (Group 2); and 3) usual-care controls with no smart insoles or education (Group 3) using a software/random table. Study personnel will be instructed not to randomize until subjects have been confirmed to meet all the inclusion/exclusion criteria. An independent offsite investigator who is not involved in the enrollment or assessment of participants will be responsible for keeping the randomization schedule in sealed envelope. After the baseline assessment, the independent offsite investigator will open an opaque envelope sequentially and assign eligible participants to each group. Participants will be blinded to their allocated groups. Thus, this trial will be a single-blinded randomized control trial. Only the research team and the statistician will be aware of treatment allocation until the end of the study. Study procedures All participants will be invited to attend the baseline visit and two-three other visits by participants in groups 1 and 2 respectively. Data at every visit will be collected in case report forms (CRFs) by the trial team. Research assistants (i.e., data collectors) will enter all data into a secure database. In the current trial and further ancillary studies, there are no plan for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis. Baseline Visit When the potential participants return for the baseline visit, the research staff will use a scripted protocol to explain the study and the consent form. All questions raised by participants will be addressed, and potential participants will be invited to participate in the study. If an individual agrees, a consent form will be obtained. The following will be performed: (1) review the study with the subject and obtain written informed consent and Health Insurance Portability and Accountability Act of 1996 (HIPPA authorization); (2) assign subjects a unique screening/enrollment number; (3) review and record medical history, surgical history, and medication history to determine eligibility based on inclusion/exclusion criteria; (4) record demographics (age, race, ethnicity, gender); (5) document height, weight (Body Mass Index [BMI]), Blood glucose and Hemoglobin A1C; (6) document all current medications including medications over-the-counter and herbal medications; (7) perform foot examinations; and (8) administer screening questioners MMSE, Foot-Care Knowledge and Practice, Foot-Care Confidence Scale. Data collection procedure Evaluate the efficacy of smart insoles with real-time alert component +foot self-care education H1 , to improve adherence to prescribed footwear and offloading in people with diabetes and at high risk for DFU. To achieve this hypothesis, Orthimeter (Germany) will tag patients’ diabetic shoes. The system has 1-year battery life and enables continuous measuring adherence to footwear by measuring temperature. Adherence to footwear will be assessed every 2 months until 6 months or incidence of ulcers. Daily Adherence to Device Wear in hours (Sensor Data and Self-Report Questionnaire): participants will gather adherence data objectively using data recorded by the sensors and compared to subjective reports. The questionnaire will ask participants to estimate their wear time per day as 0-2 hours, 2-4 hours, 4-6 hours, 8-10 hours, or 10+ hours. To determine acceptability, ease of use, and perception of benefit, we will use a Technology Acceptable Model (TAM) tailored for the study. TAM will assess users’ perception of benefits, acceptability, and ease of use with the wearable device. Participants will provide information on how strongly they agree or disagree with statements regarding benefits, acceptability, and ease of the wearable device on a 5-point scale with the following anchor: 1) strongly disagree, 2) somewhat disagree, 3) neutral, 4) somewhat agree, and 5) strongly agree. An average of four or higher indicates successful achievement on the TAM. We will also assess for the following: Foot Self-Care Knowledge and Practice, which has 15 questions on knowledge and 15 questions for practice. Cronbach’s alpha for the knowledge scale is 0.79, and practice is 0.72. Diabetes Foot-Care Behavior Self-Efficacy The Foot Care Confidence Scale will be used to test foot care self-efficacy. Comprising 12 items, with Cronbach’s alpha of from 0.78 - 0.92. Our assumptions are that H1 : Participants randomized to the smart insole + foot self-care education group will be more adherent (as confirmed by sensor data and self-report questionnaire) to footwear and offloading after 6 months, compared to participants randomized to the smart insoles and usual-care groups. H2: Changes in adherence will be mediated by self-efficacy and perception of benefits. Self-efficacy will be assessed baseline and 6 months with the Foot Care Confidence Scale (FCCS), while perception of benefits will be assessed 2, 4, and 6 months with TAM. While TAM will test for perception of benefits. H3 : Participants randomized to the smart insole + foot self-care education group will have higher acceptability and perception (as confirmed by TAM) of the benefits of their intervention, compared to those randomized to the smart insoles only and usual-care control groups. Follow-up visits There will be a biweekly visits in the first month, 2, 4, and 6 months, 30-minute one-on-one follow-up phone discussion (i.e., daily foot hygiene and cleanliness, foot protection, use of insoles and smart watch, adverse effects, addressing feedback and questions regarding the intervention and prevention of foot-related complications) on participants in groups 1 and 2. Participants in groups 1 and 2 will also return for a group visit within 1-3 weeks post baseline for intervention (group 1 receiving both foot self-care foot education as well as insoles fitting on their diabetic shoes as well as the smart watch while group 2 will only receive only insoles on their diabetic shoes and smart watch). Participants in groups 1 and 2 will be followed for additional 2, 4, and 6 months to assess for daily adherence of device wear, successful response rate to alert and duration, user perception of benefits, acceptability, and ease of use of device among others. While participants in group 3 will be followed for 2, 4, and 6 months. At 6 months, all participants including those in the usual care group 3 will return for the following: (1) assess adverse effects; (2) assess for complications following treatments; (3) document current medications including over-the-counter and herbal medications; (4) perform foot examinations and document any foot ulcers or complications; (5) document height, weight (Body Mass Index [BMI]); (6) blood glucose and Hemoglobin A1C; and (7) administer screening questioners (Foot-Care Knowledge and Practice, Foot-Care Confidence Scale, TAM, Research Activity Log, Sensor Data and Self-Report and Successful Response rate to Alert and Unresponded Alert Duration). At each visit, if participants make a withdrawal request or are not eligible to continue due to the presence of severe concomitant diseases or conditions listed in the exclusion criteria, they will be discontinued from the study. For participants who drop out, the following information including the incidence of foot ulcer; footwear and offloading adherence, plantar pressures (if possible), as well as administer study questionnaires (Foot-Care Knowledge and Practice, Foot-Care Confidence Scale) will be collected. All subjects are free to withdraw from participation at any time, for any reason, specified or unspecified, and without prejudice. Reasonable attempts will be made by the investigator to provide a reason for subject withdrawals. The reason for the subject’s withdrawal from the study will be specified in the subject’s source documents and workbook on foot-care strategies and pamphlets for self-guidance. If a subject is withdrawn due to adverse effects (such as diabetic ulcers), the subject will be followed and treated by the investigators until the abnormal parameter of symptoms has resolved or stabilized. The investigators must make every effort to contact subjects who are lost to follow-up. Attempts to contact such subjects must be documented in the subject’s records (e.g., times and dates of attempted telephone contact, receipt for sending a registered letter, etc.). To improve participants’ retention and complete follow-up, the following measures will be adopted: participants’ contact information as well as contact information for at least two persons who would know the participants’ whereabouts and could get messages to them; assign a “coach” from the team who will develop relationships, reinforce participation, and help overcome barriers that can lead to study withdrawal; and compensate for study-related visits at $50 for each visit. Interventions A 6-month intervention consisting of ( Baseline: Weeks 1-3 ): 1) contacting prospective participants, 2) screening, 3) completing informed consent, and 4) randomization. Week 4 : A 90-minute group session to educate patients on foot self-care strategies (daily foot hygiene and cleanliness, foot protection, use of insoles and smart watch). Participants (72 participants) will be randomized (24 per group) into 3 groups: 1) smart insoles + education (Group 1); 2) smart insoles (Group 2); and 3) usual-care controls with no smart insoles or education (Group 3). Insoles with Smart Watches Smart insole with an alert watch (the SurroSense RX system, Orpyx Medical Technologies, Inc., Calgary, Ca, Fig. 1) [14], is for cuing plantar pressure offloading during activities of daily living [14]. Each insole consists of eight individual pressure sensors: three distributed across the metatarsal heads, two distributed along the lateral plantar surface, and one distributed at the heel, one distributed at the great toe, and one in the distribution of the lateral toes. [14]. The insoles collect pressure information from the plantar surface of the foot and wirelessly transmit this information to the smart watch worn by participants. The device alerts the user when “safe” pressure and time thresholds are exceeded [14]. These thresholds are based on the clinical understanding of pressure ulcer formation, which indicates that a conservative threshold would be >35-50 mmHg for >15 minutes. If > 95% of measurements taken by a single sensor over a 15-minute scanning window exceed 35-50 mmHg, an alert will be sent to the user via the smart watch to guide him/her to appropriately offload that area. A successful response to an alert is defined as a pressure offloading occurring within 20 minutes of alert onset [14]. Foot Self-Care Education Contents for the foot self-care education are adapted from standard diabetes organization [2, 39-42], comprising information (i.e., risk factors of diabetes foot complications, foot self-examination, daily foot hygiene and cleanliness, foot protection, prevention of foot-related complications, and need for an annual evaluation by a healthcare professional) [2, 39-42]. A foot-care package, consisting of a pamphlet on foot self-care, a nail clipper, a water-based lotion, and a small towel will be provided to each participant. Participation in Group Education Program and Follow-up Telephone Calls A 90-minute group educational session will be conducted once in person in a conference room at the study centers. The educational session will cover foot-care strategies (i.e., risk factors of diabetes foot complications, foot self-examination, daily foot hygiene and cleanliness, foot protection, prevention of foot- related complications, benefits of wearing prescribed diabetic footwear, using smart insole with smart watch, and need for an annual evaluation by a healthcare professional) [2, 38-41]. A call will be conducted every 2 weeks to follow-up on participants’ progress and address concerns for groups 1 and 2. Participants will be advised to call the research staff with questions and concerns at any time. Participants’ Information Each participant in group 1 will receive a workbook on foot-care strategies and pamphlets for self-guidance. In addition, all participants in each group will receive a foot care package (i.e., pamphlet, nail clipper, water-based lotion, and small towel) [42]. Participants are expected to keep the workbook, pamphlet, and foot-care package at the end of the study. Outcome measures Primary Outcomes Primary outcome measures are adherent to footwear and offloading. To objectively monitor adherence to the prescribed shoes, participants’ shoes will be tagged by a miniaturized temperature + a radio-frequency identification (RFID) sensor named Orthimeter (Germany). The pressure sensing device is equipped with audio-visual alerts and offloading instructions when sustained elevated pressures are detected. The system enables continuous monitoring of the individual’s adherence to wearing the prescribed diabetic footwear. Secondary Outcomes Secondary outcome measures are incidence of diabetic foot ulcers (DFUs) measured by self-report and foot examinations by the podiatrist and study team. DFU is defined as a full-thickness wound, through the dermis, below the ankle on weight-bearing or exposed surface in an individual with diabetes [67]. We will also monitor for improved foot self-care knowledge and Practice with Foot Self-Care Knowledge and Practice baseline and at 6 months. Foot Self-Care Knowledge and Practice has 15 questions on knowledge and 15 questions for practice. Cronbach’s alpha for the knowledge scale is 0.79, and practice is 0.72 [45, 46]. In addition, we will monitor for daily adherence to device wear in hours and off-loading at 2, 4, and 6 months with the sensor data and self-report. To enhance retention and compliance, participants will undergo a detailed orientation and cognitive evaluation (e.g., Mini Mental State Examination [MMSE]) [49]. A score of MMSE <20 indicates mild degree of impairment and participants will not be enrolled in the study [49]. Perception of benefit, acceptability, and ease of use measured by the TAM [14]. Participants will provide information on how strongly they agree or disagree with statements regarding benefits, acceptability, and ease of the wearable device on a 5-point scale with the following anchor: 1) strongly disagree, 2) somewhat disagree, 3) neutral, 4) somewhat agree, and 5) strongly agree. An average of 4 or higher indicates successful achievement on the TAM [14]. A mediation outcome self-efficacy will be assessed at baseline and 6 months by the Foot Self-Care Knowledge and Practice [46, 47] and Diabetes Foot-Care Behavior Self-Efficacy [47, 48]. Our assumptions are that H1 : Participants randomized to the smart insole + foot self-care education group will be more adherent (as confirmed by sensor data and self-report questionnaire) to footwear after 6 months, compared to participants randomized to in the smart insoles and usual-care groups. H2: Changes in adherence will be mediated by self-efficacy and perception of benefit. The Foot Care Confidence Scale will assess for self-efficacy; a 12 items scale with a Cronbach’s of from 0.78 - 0.92 in those with diabetes who monitored for foot ulcer [48]. While TAM will test for perception of benefits. H3 : Participants randomized to the smart insole + foot self-care education group will have higher acceptability and perception (as confirmed by TAM) of the benefits of their intervention, compared to those randomized to the smart insoles only and usual-care control groups. Demographics and clinical indicators Participants’ characteristic of age, weight, body mass index, current medication issues, current medications, diabetes history, other chronic diseases such as high blood pressure, periphery artery diseases, neuropathy will be collected using electronic case report forms. Participants will be asked for number and types of medications taken, medication scheduling, and the dose used to self-manage diabetes as well as DFU symptoms at baseline and at 6 months. Data management Data monitoring All researchers including investigators, data collectors (i.e., research assistants), study coordinators, site monitors, data managers, outcome assessors, and statistician will receive special training regarding the standard procedure and data management. The Principal Investigator will be responsible to ensure the study is conducted in accordance with the protocol, Good Clinical Practice (GCP), applicable regulatory requirements, and that the data recorded is valid. To achieve this objective, the study will be continuously monitored and reviewed in a monthly basis by the study team. Clinical site monitoring is conducted to ensure that the rights and well-being of human subjects are protected, that the reported trial data are accurate, complete, and verifiable, and that the conduct of the trial complies with the currently approved protocol/amendment(s) with GCP, and with applicable regulatory requirements(s). A Clinical Monitoring Plan will be created by the Sponsor and describe in details as well as who will conduct the monitoring, and the distribution of monitoring reports. Data handling and record keeping The collection of personal patient information will be limited to the amount necessary to achieve the aims on the research, so that no unneeded sensitive information is being collected. Only study personnel will collect data. Hard copy documents will be retained for the duration of the study until data entry and will be saved for at least 5 years after publication. All hard copy documents related to the research will be saved in a locked filling cabinet of GCP at MEDVAC/BCM, while electronic documents will be stored in a special computer with protected password. Data will be exported into the Excel or SAS file format (password protected), which will then be used for data analysis. Only de-identified data will be used for data analysis. Collected de-identified data will be sent to a biostatistician for statistical analysis. If readers have any questions about our published data, they could contact our corresponding author (i.e., the principal investigator) to obtain the original data. Statistical Analysis At the end of this trial, all original data without participants’ name and the random sequences will be sent to a statistician for data analysis. Data will be downloaded from each smart watch and analyzed, using SPSS (IBM, version 25, Chicago IL) and MPlus v7.3 [68]. To identify possible predictors of adherence rates, participants will be categorized, based on whether they responded to alert or not (HA: high-alert group) or less (LA: low-alert group) defined as one alert every 2 hours that the device is worn. Intent-to-treat procedures will be used to treat the missing data on the outcomes for Aim 1-H1. Results will be expressed as means ± standard deviation (SD). Repeated measures ANOVA will be used to compare adherences among the three groups at 2 months and 6 months. If overall significance is found, post hoc comparison using Tukey’s test will be used to examine the adherence difference between every two groups. If assumption of homogeneity of variables is violated Games-Howell post hoc test will be used instead. Pearson’s correlation analysis will be used to examine correlation between changes in adherence over 2 months to 6 months and number of alerts triggered per hour in each group. Cohen’s d effect size will be used to estimate mean- difference effect sizes between groups. Cohen’s d value of 0.2, 0.5, and 0.8 will be considered small, medium, and large effect sizes, respectively [14, 50]. Latent growth curve mediation model will be used to test the effect of the combined smart insole and foot self-care education on improving adherence to footwear at every 2 months till 6 months, in which time points will be used as repeated measures, baseline demographics and treatment will be included as first level fixed effect, participants will be as second level random effect, and perception/self-efficacy will be the third level random effect . Mixed models accommodate the longitudinal design with random effects; allow for testing differences between groups in patterns over time as well as at specific time points;, and are valid for data which are missing completely at random or at random (2). Latent growth models are particularly used in the mediation analysis to examine the individual trajectory change over 6 months of period and that a relatively large intra-individual change is anticipated. All statistical analyses will be performed using SPSS (IBM, version 25, Chicago IL) and MPlus v7.31, with a significance level of P < .05. Discussion Over the years, well-designed RCTs have failed to produce outcomes in terms of preventing initial and recurrent DFU in individuals at risk for DFU. Previous studies show that adherence to prescribed diabetic footwear and offloading harmful plantar pressures are critical in preventing DFU in at risk individuals (i.e., those with peripheral neuropathy, PAD). The question remains why these diabetic foot wears or the numerous offloading devices (i.e., smart insoles with alert device) among others recommended for patients are not addressing the overwhelming incidences of DFU seen in individuals at high risk for DFU. A lower-limb amputation due to diabetes occurs every 20 seconds, of which 85% are preceded by foot ulceration [68]. Diabetic footwear is recommended for all patients at risk for diabetes foot ulcers. Diabetic footwear decreases incidence of DFUs and reulceration. While offloading harmful pressure areas that can lead to DFU is gaining momentum about preventing DFU in at risk individuals with diabetes. There is evidence that elevated plantar pressure contributes to the development of DFU, which makes relief of mechanical pressure (also called offloading) a recommended approach. A recent study by Najafi and colleagues demonstrated the efficacy and feasibility of smart insoles with real-time alerts for plantar pressure offloading in those at-risk individuals with DFU. The smart-insole device was designed to cue offloading to manage unprotected sustained plantar pressures to prevent foot ulceration. Interestingly, their study suggested that, in the group with at least one alert every 2 hours, adherence to prescribed footwear was increased or retained over time, whereas a lower number of alerts reduced adherence. The authors speculated that reduced adherence in the low-alert group may be linked to disengagement or reduced perception of benefit. It is unknown whether smart insoles with alerts improve use of footwear, offloading, and lower the incidence of DFU, compared to usual care. It is unknown whether self-efficacy will mediate performance accomplishments (use of smart insoles+ smart watch) behavior performance (wearing diabetic shoes) and desired outcomes (improve adherence to diabetic footwear, improve offloading and reduce incidence of foot ulcers) in those at risk for DFU. In the present study, we are proposing a RCT to assess whether a modern technology (i.e., alert-base insoles plantar offloading device) plus foot self-care education will improve adherence to prescribed footwear, improve offloading harmful foot pressure areas, and reduce the incidence of DFU in those at-risk individuals with diabetes. As a multifaceted intervention, we speculate the proposed intervention has the potential to: 1) increase adherence and increase perception of benefit of prescribed footwear; 2) release individuals from the substantial burden of having to endure countless DFUs as a result of having diabetes; 3) raise awareness and knowledge of early intervention to prevent DFU, which, in turn, will prevent severe and costly outcomes in diabetes care; 4) provide information that can potentially advance the way DFU is managed in clinical practice; and 5) provide valuable preliminary knowledge to guide future research on the use of technology for an optimal preventive approach to prevent initial and recurrent DFU in at -risk individuals with diabetes. At the end of this trial, we will compare the results from this study with previous RCTs about adherence to prescribed footwear and offloading devices in the prevention of DFU. Result from previous studies show that these sustained high plantar pressures are managed through passive methods, such as orthotics, medical arch support, Rocker shoes, and custom insoles, which are not effective in reducing pressure in certain areas of the foot [14, 24]. Due to the passivity of these devices, users are limited to physically altering the architecture of the foot and are not encouraged to adjust their behavior by offloading harmful pressure areas [14]. Studies show that proper prevention of foot ulcers should consider the importance of foot biomechanics and patient behavior [2]. The current standard of care for preventing foot ulcers includes screening for foot ulcers, risk classification, regular foot care, protective shoes and insoles, and diabetic foot education [14, 33]. Increasingly, studies have begun to use feedback devices to help at risk populations avoid negative outcomes [14, 34, 35]. The smart insole with an alert technology we are proposing is designed with sensors that monitor continuous plantar pressure and provide the user with alert-based feedback when plantar pressures are too high [14, 36]. It has been determined, however, that this smart insole, together with an alert-based feedback system, (a) successfully notified patients of harmful pressures (b) has been proven to be effective and acceptable by high-risk diabetic patients, and (c) may enhance adherence to prescribed footwear. Adherence to diabetic footwear and prevention of foot ulcers in patients with diabetes will require an integrated approach of patient education on foot self-care and wearing therapeutic or prescribed footwear [3]. Adherence to a treatment regime is confirmed to play a key role in clinical outcome [3, 13, 30]. Interventions targeting those with diabetes and at risk for DFUs are urgently needed to help clinicians treating patients with diabetes. Previous integrated approaches do not involve state-of-the art interventions or specific knowledge about factors that increase sustained adherence to footwear, prevention, or prediction of DFU recurrence [3]. Our proposed study is an integrated approach that will not only address ways to improve sustained adherence to footwear, but also potentially prevent initial appearance and recurrence of foot ulcer. Education alone does not improve the use of diabetic footwear and diabetes foot self-care behaviors [6, 11]. Although education aiming to promote foot self-care to prevent foot lesions has been widely advocated and implemented in standard practice, evidence for the effectiveness in improving sustained adherence to prescribed footwear and prevention of foot ulcer is still scarce [6]. Patient education has different methods (e.g., individual or group sessions), different length of treatment (e.g., single, or weekly sessions), different educators (e.g., nurses, podiatrists, physicians) and different delivery methods (e.g., video chat, telephone) [13]. The most beneficial patient education that can lead to sustained adherence to prescribed footwear in at-risk individuals with diabetes has yet to be investigated [13]. Many educational interventions of foot self-care focus primarily on improving self-management behavior [9, 13, 31, 32], which is beneficial, but lacks evidence within the scope of sustained adherence to prescribe footwear and foot-ulcer prevention [13]. The current proposal represents an unprecedented opportunity to support the hypothesis that an integration of alert-based insoles for plantar pressure offloading and foot self-care education will result in increased and sustained adherence to prescribed diabetes footwear, improve offloading of harmful pressure foot areas and will, ultimately, prevent future DFUs [3]. Ethics and Dissemination The study will be completed in accordance with the ethical principles in the Declaration of Helsinki and the International Conference on Harmonization (ICH) GCP Guideline. Texas Woman’s University and Baylor College of Medicine will be primary sites for the study and will monitor and audit this project to ensure compliance with the necessary legislation. The protocol, informed consent form(s), and all pertinent data collection materials were submitted to the IRB for review and prior approval. This is a low-risk trial because therapeutic footwear and smart insoles with a smart watch are non-invasive and will be delivered by a trained, registered podiatrist, nurse, or vascular surgeon. Any adverse events will be recorded by investigators and reported to the trial team. Participants will also be offered the opportunity to report any adverse events at follow-up assessments. At the end of the trial, we will present our findings at the national and international conferences and peer reviewed nursing and medicine journals. Trial Status This protocol was approved 15 September 2021. Recruitment of participants will commence approximately in July 2022. Recruitment will be stopped automatically as soon as 72 participants have been included, which will be completed approximately July 2024. Abbreviations DFU Diabetic foot ulcer ED Emergency room BCM Baylor College of Medicine MEDVAMC Michael E. DeBakey VA Medical Center TWU Texas Woman’s University CONSORT Consolidated Standards of Reporting Trials SPIRIT iCAMP:Interdisciplinary Consortium on Advanced Motion Performance DFN Diabetes peripheral neuropathy PAD Peripheral artery disease MOCA Montreal Cognitive Assessment RCT Randomized Clinical Trials CRF H:Hypothesis TAM Technology Acceptable Model BMI Body Mass Index LA Low-Alert GCP Good Clinical Practice SD Standard Deviation IBM International Business Machines Corporation ICH International Conference on Harmonization IRB HIPPA:Health Insurance Portability and Accountability Declarations Acknowledgements We thank Dr. Madhura and Ms. Lindsey for their support as investigator wrote the proposal. Authors’ contributions The authors’ responsibilities were as follows: NDM and BN designed the study. NMD conducted the systematic review including the foot self-care education and intervention. WW completed the sample size calculations and constructed the randomization and data analysis. All authors critically appraised the protocol and approved the final manuscript. Funding This study is funded and sponsored in part by the Texas woman’s University (Support research) and COMRADE Grant # R25NS094093-02. The sponsor has not taken part in the study design. Availability of data and material Not applicable Ethics approval and consent to participate Ethics approval was obtained from the Texas Woman’s University Institutional Review Board (IRB) in Houston Campus, Texas-United States. Consent for publication Not applicable Competing interests The authors have no relevant afflictions or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject, matter or matters discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants, or patients received or pending, or royalties. Authors’ information NDM, PhD, Assistant Professor, Texas Woman’s University, Nelda C. Stark, College of Nursing 6700 Fannin Street Houston, TX 77030. United States. WW, PhD, Statistician Texas Woman’s University, Center for Research Design and Analysis, Office of Research and Sponsored Programs. 6700 Fannin Street Houston, TX 77030. United States. Bijan Najafi, PhD, Professor of Surgery, Director of Clinical Research at Division of Vascular Surgery and Endovascular Therapy, Michael E. DeBakey Department of Surgery, Baylor College of Medicine and Director of Interdisciplinary Consortium on Advanced Motion Performance (iCAMP), McNair Campus, Houston, Texas-United States. References Maciejewski ML, Reiber GE, Smith DG, Wallace C, Hayes S. Effectiveness of diabetic therapeutic footwear in preventing reulceration. Diabetes Care . 2004;27(7):1774-1782. Bus SA, van Netten JJ, Lavery LA, Monteiro-Soares M, Rasmussen A, Jubiz Y, et al. IWGDF Guidance on the prevention of foot ulcers in at-risk patients with diabetes. International Working Group on the Diabetic Foot. 2016. http://www.d-foot.org/d-foot/wpcontent/uploads/_PDF/RESOURCES/Guideline%20Prevention.pdf. Accessed 20 Jan 2020. Armstrong DG, Boulton AJM, Bus SA. Diabetic foot ulcers and their recurrence. N Engl J Med . 2017;376(24):2367-2375. doi:10.1056/NEJMra1615439. Fan L, Sidani S, Cooper-Braithwaite A. Feasibility, acceptability, and effects of a foot self-care education intervention on minor foot problems in adult patients with diabetes at low risk for foot ulceration: A pilot study. Can J Diabetes . 2013;37(2013):195-201. Prompers L, Huijberts M, Apelqvist J, et al. High prevalence of ischemia, infection, and serious comorbidity inpatients with diabetic foot disease in Europe. Baseline results from the Eurodiale study. Diabetologia . 2007; 50:18-25. doi:10.1007/s00125-006-0491-1. Frykberg RG, Lavery LA, Pham H, Harkless L, Veves A. Role of neuropathy and high foot pressures in diabetic foot ulceration. Diabetes Care . 1998;21(10):1714-1719. Dorresteijn JAN, Kriegsman DMW, Assendelft WJJ, Valk GD. Patient education for preventing diabetic foot ulceration (Review). Cochrane Database Syst Rev . 2014;12(CD001488):1-53. doi: 10.1002/14651858.CD001488.pub5. Unwin N. Epidemiology of lower extremity amputation in centres in Europe, North America, and East Asia: The Global Lower Extremity Amputation Study Group. Br J Surg . 2000; 87:328-337. Pecoraro RE, Reiber GE, Burgess EM. Pathways to diabetic limb amputation. Basis for prevention. Diabetes Care . 1990;13(5):513-521. doi:10.2337/diacare.13.5.513. Corbett Cf. A randomized pilot study of improving foot care in home health patients with diabetes. Diabetes Educ . 2003; 29:273-282. doi:10.1177/014572170302900218. Dorresteijn JAN, Kriegsman DMW, Assendelft WJJ, Valk GD. Patient education for preventing diabetic foot ulceration (review). The Cochran Library . 2012; 10:1-51. Schaper NC, Van Netten JJ, Apelqvist J, et al. Prevention and management of foot problems in diabetes. A summary guidance for daily practice based on the 2015 IWGDF Guidance Documents. Diab Metab Res Rev . 2016;32(Suppl 1):7-15. doi:10.1002dmrr.2695. van Netten JJ, Price PE, Lavery LA, et al. Prevention of foot ulcers in the at-risk patient with diabetes: A systematic review. Diabetes Metab Res Rev . 2016;32(1):84-98. doi:10.1002/dmrr.2701. Najafi B, Ron E, Enriquez A, Marin I, Razjouyan J, Armstrong DG. Smarter sole survival: Will neuropathic patients at high risk for ulceration use a smarter insole-based foot protection system? J Diabetes Sci Technol . 2017;11(4):702-713. doi:10.1177/1932296816689105. Boulton, AJM, Whitehouse RW. The Diabetic Foot. [Updated 2020 Mar 15]. In: Feingold KR, Anawalt B, Boyce A. et al., editors [Internet]. South Darmouth (MA): MDText.com, Inc.; 200-, https://www.ncbi.nlm.nih.gov/books/NBK409609/. Accessed 12 Nov 2021. Kerr M, Rayman G, Jeffcoate WJ. Cost of diabetic foot disease to the National Health Service in England. Diab Med . 2014;31(12):1498-1504. doi:10.1111/dme.12545. Thewjitchatoen Y, Sripatpong J, Krittiyawong S. et al. Changing the patterns of hospitalized diabetic foot ulcer (DFU) over a 5-year period in a multi-disciplinary setting in Thailand. BMC Endocr Disord 2020; 89. https://doi.org/10.1186/s12902-020-00568-7 . Zhang P, Lu J, Tang S, Zhu D, Bi Y. Global epidemiology of diabetic foot ulceration: A systematic review and meta-analysis. Ann Med . 2017;49(2):106-116. doi:10.1080/07853890.2016.1231932. Tennvail GR, Apelqvist J. Health-economic consequences of diabetic foot lesions. Clin Infect Dis . 2004;39(Suppl 2): S132-139. doi:10.1086/383275. Rice JB, Desai U, Cummings AK, Birnbaum HG, Skornicki M, Persons NB. Burden of diabetic foot ulcers for mediocre and private insurers. Diabetes Care . 2014;37(3):651-8. doi:10.2337/dc13-2176. Miller JD. Salloum M, Button A, Giovinco NA, Armstrong DG. How can I maintain my patient with diabetes and history of foot ulcer in remission? Int J Low Extrem Wounds . 2014;13(4):371-377. doi:10.1177/1534734614545874. Veves A, Murray HJ, Boulton AJ. The risk of foot ulceration in diabetic patients with high foot pressure: A prospective study. Diabetologia . 1992;35(7):660-663. Waaijman R, de Haart M, Arts ML, Wever D, Verlouw AJ, Nollet F, Bus SA. Risk factors for plantar foot ulcer recurrence in neuropathic diabetic patients. Diabetes Care . 2014;37(6):1697-705. doi:10.2337/dc13-2470. Bus SA, Ulbrecht JS, Cavanagh PR, Pressure relief and load redistribution by custom-made insoles in diabetic patients with neuropathy and foot deformity. Clin Biomech (Bristol, Avon). 2004;19(6):629-38. doi: 10.1016/j.clinbiomech.2004.02.010. American Podiatric Medical Association. Diabetes by the numbers: South Dakota. https://www.apma.org/files/FileDownloads/DiabetesbytheNumbers_South%20Dakota.pdf. Accessed 11 Nov 2021. Meloni M, Izzo V, Giurato L, Lazaro-Martinez JL, Uccioli L. Prevalence, Clinical Aspects and Outcomes in a Large Cohort of Persons with Diabetic Foot Disease: Comparison between Neuropathic and Ischemic Ulcers. J. Clin. Med. 2020, 9(6), 1780; https://doi.org/10.3390/jcm9061780. Lipsky BA, Berendt AR, Cornia PB et al. 2012 Infectious Diseases Society of America clinical practice guideline for the diagnosis and treatment of diabetic foot infections. Clin Infect Dis . 2012;54(12): e132-73. doi:10.1093/cid/cis346. Lavery LA, Armstrong DG, Wunderlich RP, Tredwell J, Boulton AJ. Diabetic foot syndrome: evaluating the prevalence and incidence of foot pathology in Mexican Americans and non-Hispanic whites from a diabetes disease management cohort. Diabetes Care . 2003;26(5):1435-1438. doi:10.2337/diacare.26.5.1435. Skrepnek GH, Armstrong DG, Mills JL. Open bypass, and endovascular procedures among diabetic foot ulcer cases in the United States from 2001 to 2010. J Vasc Surg . 2014;60(5):1255-1265. doi: 10.1016/j.jvs.2014.04.071. Bus SA, van Deursen RW, Armstrong DG, Lewis JE, Caravaggi CF, Cavanagh PR. Footwear and offloading interventions to prevent and heal foot ulcers and reduce plantar pressure in patients with diabetes: A systematic review. Diabetes Metab Res Rev . 2016;32(Suppl 1):99-118. doi:10.1002/dmrr.2702. Barth R, Campbell LV, Allen S, Jupp JJ, Chisholm DJ. Intensive education improves knowledge, compliance, and foot problems in type 2 diabetes. Diabet Med . 1991;8(2):111-7. doi:10.1111/j.1464-5491. 1991.tb01555. x. Borges WJ. The impact of a brief foot care intervention for persona with diabetes. University of Texas Health Science Center at Huston School of Nursing; 2004. https://www.researchgate.net/publication/28789862. Accessed 11 Nov 2021. Lavery LA, Fontaine J, Kim PJ. Preventing the first or recurrent ulcers. Med Clin North Am. 2013; 97:807-820. Berengueres J, Fritschi M, McClanahan R. A smart pressure-sensitive insole that reminds you to walk correctly: An orthotic-less treatment for over pronation. Ann Int Conf Proc IEEE Eng Med Biol Soc . 2014; 2014:2488-2491. doi:10.1109/EMBC.2014.6944127. Ferber R, Webber T, Everett B, Groenland M. Validation of plantar measurements for a novel in-shoe plantar sensory replacement unit. J Diabetes Sci Technol . 2013;7(5):1167-75. doi:10.1177/193229681300700535. Farhad F, Gray LC, Russell AW. A Clinimetric Study of outpatient diabetes consultations: The potential for telemedicine substitution. Diabetes Technol Ther . 2014;16(1):8-14. doi:10.1089/dia.2013.0213. Mbue ND, Wang J, Cron SG, Anderson JA. A multiple behavior self-monitoring intervention for African American Veterans with type 2 diabetes: A feasibility implementation study. J Natl Black Nurses Assoc . 2017;28(1):1-8. Bandura A. Self-efficacy: Toward a unifying theory of behavioral change. Psychol Rev . 1977;84(2):191-215. doi:10.1037//0033-295x.84.2.191. American Diabetes Association. Standards of Medical Care in Diabetes-2017. J Clin Applied Res Educ . 2017;40(1):1-142. National Institute for Health and Care Excellence. Diabetic foot problems: Prevention and management. 2019. https://www.nice.org.uk/guidance/ng19. Accessed 11 Nov 2021. Amputation Prevention Reports-British Columbia-Diabetes. https://www.diabetes.ca/newsroom/search-news/mortality-rate-of-diabetic-foot-disease. Accessed 11 Nov 2021. Registered Nurse’ Association of Ontario. Assessment and management of foot ulcers for people with diabetes, second edition-201. https://rnao.ca/sites/rnao ca/files/Assessment_and_Management_of_Foot_Ulcers_for_People_with_Diabetes_Second_Edition1.pdf. Accessed 11 Nov 2021. Sharoni SKA, Rahman HA, Minhat HS, Ghazali SS, Ong MHA. A self-efficacy education programme on foot-self-care behavior among older patients with diabetes in a public long-term care institution, Malaysia: A quasi-experimental pilot study. BMJ . 2017;7: e014393. doi:10.1136/bmjopen-2016-014393. Baylor College of Medicine. Explore research at Baylor College of Medicine. https://www.bcm.edu/research. Accessed 11 Nov 2021. Robles RB, Ortiz LGC, Quirate NHG, Berry DC Aguilera P, Martinez SP. Knowledge and practices of diabetes foot care and risk of developing foot ulcers in Mexico may have implications for patients of Mexican heritage living in the US. Diabetes Edu c. 2017;43(3):297-303. doi:10.1177/0145721717706417. Hasnian S, Sheikh NH. Knowledge and practices regarding foot care in diabetic patients visiting diabetic clinic in Jinnah Hospital, Lahore. J Pak Med Assoc . 2009;59(10):687-690. Garcia-Inzunza JA, Valles-Medina AM, Munoz FA, Delgadillo-Ramos G, Compean-Ortiz LG. Validation of the Mexican version of the combined foot care confidence/foot-care behavior scale for diabetes. Rev Panam Salud Publica . 2015;38(1):35-41. Sloan HL. Developing and testing of the Foot Care Confidence Scale. J Nurs Meas . 2002;10(3):207-218. doi:10.1891/jnum.10.3.207.52564. Mini-Mental State Examination (MMSE). https://www.http://www.fammed.usouthal.edu/Guides&JobAids/Geriatric/MMSE.pdf. Accessed 11 Nov 2021. Cohen J. Statistical Power Analysis for the Behavioral Sciences . New York, NY: Routledge; 2013. Abbot CA, Chatwin KE, Foden P, et al. Innovative intelligent insole system reduces diabetic foot ulcer: A prospective, randomized, proof-of-concept study. Lancet Digit Health . 2019;1(6): e308-e318. doi:10.1016/S2589-7500(19)30128-1. Sicco AB, Lavery LA, Monteiro-Soares M, et al. IWGDF Guideline on the prevention of foot ulcers in person with diabetes-2019. https://iwgdfguidelines.org/wp-content/uploads/2019/05/02-IWGDF-prevention-guideline-2019.pdf. Accessed 11 Nov 2021. Jarl G. Methodological considerations of investigating adherence to using offloading devices among people with diabetes. Patient Prefer Adherence . 2018; 12:1767-1775. doi:10.2147/PPA.S175738. Oori MJ, Mohammadi F, Norouzi K, et al. Conceptual model of medication adherence in older adults with high blood pressure-An integrated review of the literature. Curr Hypertens Rev . 2019;15(2):85-92. doi:10.2174/1573402114666181022152313. Waaijman R, Keukenkamp R, Haart M, et al. Adherence to wearing prescription custom-made footwear in patients with diabetes at high risk for plantar foot ulceration. Diabetes Care . 2013;36(6):1613-8. doi:10.2337/dc12-1330. Knowles EA, Boulton AJ. Do people with diabetes wear their prescribed footwear? Diabet Med . 1996;13(12):1064-1068. doi:10.1002/(SICI)1096-9136(199612)13:123.0.CO;2-#. McCabe CJ, Stevenson RC, Dolan AM. Evaluation of a diabetic programme. Diabet Med . 1998;15(1):80-84. Neibauer G. The diabetic Foot-2017. https://alpinefoot.com/. Accessed 11 Nov 2021. American Diabetes Association. Standards of Medical Care in Diabetes-2020. Clinical Diabetes, 2020; 38(1): 10-38. https://doi.org/10.2337/cd20-as01. Mineka S, Watson D, Clark LA. Comorbidity of anxiety and unipolar mood disorder. Annu Rev Psychol . 1998; 49:377-412. doi: 10.1146/annurev.psych.49.1.377. Aseri ZA, Suriya MO, Hassan HA, et al. Reliability and validity of the Hospital Anxiety and Depression Scale in an emergency department in Saudi Arabia: A cross-sectional observational study. BMC Emerg Med . 2015; 15:28. doi:10.1186/s12873-015-0051-4. Zimet GD, Dahlem NW, Zimet SG, Farley GK. The Multidimensional Scale of Perceived Social Support . J Pers Assess . 1988; 52:30-41. doi:10.1207/s15327752jpa5201_2. Wongpakaran T, Wongpakaran N, Ruktrakul R. Reliability, and validity of the Multidimensional Scale of Perceived Social Support (MSPSS): Thai version. Clin Pract Epidemiol Ment Health . 2011; 7:161-166. doi:10.2174/1745017901107010161. Centers for Disease Control and Prevention. National Diabetes Statistics Report, 2020. https://www.cdc.gov/diabetes/library/features/diabetes-stat-report.html. Accessed 9 July 2021. Alfonso AR, Smita Rao PT, Everett B, Chiu ES. Novel pressure-sensing smart insole system used for the prevention of pressure ulceration in the insensate foot . Plast Reconstr Surg Glob Open . 2017;5(12): e1568. doi:10.1097/GOX.0000000000001568. van Netten JJ, Raspovic A, Lavery LA, et al. Prevention of foot ulcers in the at-risk patient with diabetes: A systematic review. Diabetes Metab Res Rev . 2020;36 Suppl 1: e3270. doi:10.1002/dmrr.3270. Shin L, Armstrong D, Sanders LJ. Foot Ulcers: John’s Hopkins Diabetes Care 2020. https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_Diabetes_Guide/547054/all/Foot_Ulcers. Accessed 12 July 2021. Diabetic Foot Fact. The global burden of diabetes and foot complications: the facts. https://www.d-foot.org/diabetic-foot/diabetic-foot-facts. Accessed 11 Nov 2021. Cite Share Download PDF Status: Posted Version 1 posted You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-1099111","acceptedTermsAndConditions":true,"allowDirectSubmit":true,"archivedVersions":[],"articleType":"Research Article","associatedPublications":[],"authors":[{"id":102127715,"identity":"0103652f-7ba2-4ae2-b3a9-0780936fc689","order_by":0,"name":"Ngozi D. Mbue","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAAAk0lEQVRIiWNgGAWjYFACHiCugDAlSNByxoBULYxtpGgxFzt7TOLjvD+JGw4wH7zNQ4wWy9l5aZIztxkAtbAlWxOlxeB2jpk07zaD3A0HeMykidfydw5IC/83ErQwNoBtYSNWS16yZc8x4/qZh9mMLecQpyX34I0fNXLGfMebH954Q4wWBGAmTfkoGAWjYBSMAnwAAM5AL9vgG3ycAAAAAElFTkSuQmCC","orcid":"https://orcid.org/0000-0003-1707-0817","institution":"Texas Woman's University - College of Nursing","correspondingAuthor":true,"submittingAuthor":false,"prefix":"","firstName":"Ngozi","middleName":"D.","lastName":"Mbue","suffix":""},{"id":102127716,"identity":"7d0353d8-9906-42ff-a81a-a812bca9193a","order_by":1,"name":"Wanyi Wang","email":"","orcid":"","institution":"Texas Woman's University","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Wanyi","middleName":"","lastName":"Wang","suffix":""},{"id":102127717,"identity":"9a224fcc-1203-4255-b606-406cd70af6da","order_by":2,"name":"Bijan Najafi","email":"","orcid":"","institution":"Baylor College of Medicine","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Bijan","middleName":"","lastName":"Najafi","suffix":""}],"badges":[],"createdAt":"2021-11-20 17:17:14","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-1099111/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-1099111/v1","draftVersion":[],"editorialEvents":[],"editorialNote":"","failedWorkflow":false,"files":[{"id":21166534,"identity":"2eea92af-558c-468b-bd47-2cba51cb0b28","added_by":"auto","created_at":"2022-05-06 15:36:21","extension":"jpg","order_by":1,"title":"Figure 1","display":"","copyAsset":false,"role":"figure","size":49360,"visible":true,"origin":"","legend":"\u003cp\u003eExample of sustained harmful pressure of foot\u003c/p\u003e","description":"","filename":"Fig1.jpg","url":"https://assets-eu.researchsquare.com/files/rs-1099111/v1/c22dbad03772ba9d8464c96d.jpg"},{"id":21166535,"identity":"1d0c8865-1470-4dc2-a9b3-daba3e261752","added_by":"auto","created_at":"2022-05-06 15:36:21","extension":"jpg","order_by":2,"title":"Figure 2","display":"","copyAsset":false,"role":"figure","size":136760,"visible":true,"origin":"","legend":"\u003cp\u003eTrial flow chart\u003c/p\u003e","description":"","filename":"Fig2.jpg","url":"https://assets-eu.researchsquare.com/files/rs-1099111/v1/ece0a50fa5772f3021d401b9.jpg"},{"id":21166980,"identity":"6d005de6-5884-4735-aa3f-267193695145","added_by":"auto","created_at":"2022-05-06 15:41:21","extension":"jpg","order_by":3,"title":"Figure 3","display":"","copyAsset":false,"role":"figure","size":129188,"visible":true,"origin":"","legend":"\u003cp\u003eSchedule of enrolment, intervention, and assessment\u003c/p\u003e","description":"","filename":"Fig3.jpg","url":"https://assets-eu.researchsquare.com/files/rs-1099111/v1/b907d83fec2ac8e0bac371e5.jpg"},{"id":24756037,"identity":"b743a54c-a7e3-4e52-8279-798f83819ce4","added_by":"auto","created_at":"2022-08-04 03:00:53","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":724912,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-1099111/v1/e2197b1c-db73-4c11-98c1-15fa86653d95.pdf"}],"financialInterests":"","formattedTitle":"Benefits of Insoles with Real-Time Alert and Foot Self-Care Education in Improving Offloading and Adherence to Prescribed Footwear in Patients with Diabetes Mellitus: Study Protocol for a Single-Blinded Randomized Clinical Trial","fulltext":[{"header":"Background And Rationale","content":"\u003cp\u003eDiabetic foot ulcers (DFU) are a major complication of diabetes mellitus, with high morbidity, mortality, and resource utilization [13, 15-18]. On average, annual cost of a DFU is \u003cspan\u003e$\u003c/span\u003e8659 per individual [19], whereas the total medical cost for treatment of diabetic foot diseases in America ranged from \u003cspan\u003e$\u003c/span\u003e9 to \u003cspan\u003e$\u003c/span\u003e17 billion in 2013, an additional cost associated with diabetes management [18, 20, 21]. With the increasing number of aging individuals and individuals with diabetes in the United States every year, a high number of patients with diabetes are at risk for DFU. DFU is largely preventable, yet common in those with diabetes, with an estimated 19\u0026ndash;34% risk [3]. More than half of DFUs become infected [3, 26], with approximately 20% of diabetic foot infections leading to amputation [3, 27, 28]. Mortality after diabetes- related amputation exceeds 70% at 5 years for all patients with diabetes [3]. The societal burden of DFU exceeds that of most other health concerns and contributes to the strain on the US healthcare system [21, 29]. A report that examined over 1 million cases of DFUs seen in US emergency departments (ED) from 2006 to 2010 showed a national cost of \u003cspan\u003e$\u003c/span\u003e1. 9 billion per year for ED-related treatments of DFUs alone and \u003cspan\u003e$\u003c/span\u003e8.78 billion per year for inpatient care for these patients [14]. Even when patients receive state-of-the-art preventive care, 12-month recurrence of DFUs exceeds 40% [3]. Sustained adherence to prescribed footwear as well as offloading harmful plantar areas is essential in those with diabetes and at risk for DFU.\u003c/p\u003e \u003cp\u003eDFUs can result from multiple factors. One of the most significant factors is elevated plantar pressures in a neuropathic insensate foot [22, 14, 23], often a challenge to manage due to poor circulation associated with a neuropathic limb [2, 23]. Another significant factor is repetitive stress on the foot, particularly in the presence of neuropathy or peripheral artery disease [21]. Presently, these sustained high plantar pressures are managed through passive methods, such as orthotics, medical arch support, Rocker shoes, and custom insoles, which are not effective in reducing pressure in certain areas of the foot [14, 24]. Due to the passivity of these devices, users are limited to physically altering their behavior by offloading harmful pressure areas [14]. The ineffectiveness of the current medical approaches leads to approximately 73,000 amputations every year in the United States, with each amputation costing on average, \u003cspan\u003e$\u003c/span\u003e70,434 in 2010 [25]. Research shows that offloading harmful plantar pressures is a recommended approach [6, 7], as well as adherence to the recommended diabetic footwear. Both approaches have potential to decrease incidence of DFU and ulcer reoccurrence in those with diabetes and at risk for DFU. Progress has occurred in educating those with diabetes and at risk for diabetes foot ulcer about the importance of offloading painful plantar areas, diabetic footwear, and the prevention of foot ulcers [12]. However, limited progress is made in educating individuals about offloading and adherence to diabetic footwear. Data shows that education alone is insufficient in reducing the occurrence of first time and recurrent DFU or adherence to prescribed footwear [13]. Smart insoles with alert technology (smart watch) along with foot self-care education will offer a round -the- clock, patient-specific education, active response, and adherence to prescribed diabetic footwear and will ultimately reduce the incidence of DFUs. Offloading harmful plantar areas and adherence to diabetic footwear and the prevention of foot ulcers in patients with diabetes will require an integrated approach of patient education on foot self-care and wearing therapeutic insoles or prescribed footwear [3]. Adherence to a treatment regime is confirmed to play a key role in clinical outcomes [3, 13, 30]. Interventions targeting those with diabetes and at risk for DFUs are urgently needed to help clinicians treating patients with diabetes. Previous integrated approaches do not involve state-of-the-art interventions or specific knowledge about factors that increase sustained adherence to footwear, prevention, or prediction of DFU recurrence [3]. Our proposed study is an integrated approach that will not only address ways to improve offloading harmful plantar areas and sustained adherence to footwear, but also potentially prevent initial appearance and recurrence of foot ulcers [3].\u003c/p\u003e\n\u003ch2\u003eObjectives\u003c/h2\u003e\n\u003cp\u003eThe overall purpose of this research is to establish a novel approach to promote adherence to prescribed diabetic footwear and offload harmful plantar areas in individuals with diabetes as well as high incidence of DFU. Our research hypotheses are as follows:\u003c/p\u003e \u003cp\u003e(1) Participants with smart insole with real-time alert and foot self-care education will be more adherent to footwear and offloading over 6 months, compared to participants with smart insoles only or usual care.\u003c/p\u003e \u003cp\u003e(2) Participants with smart insole with real-time alert and foot self-care education will have higher acceptability and perception of the benefits of their intervention, compared to those randomized to the smart insoles only or usual-care control groups.\u003c/p\u003e \u003cp\u003e(3) Changes in adherence will be mediated by self-efficacy and perception of benefits.\u003c/p\u003e \u003cp\u003e(4) Participants randomized to the smart insole with real-time alert + foot self-care education will have low incidence of DFUs compared to participants randomized to the smart insoles and usual-care groups.\u003c/p\u003e"},{"header":"Methods/design","content":"\u003cp\u003e\u003cstrong\u003eTrial design\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe study was designed as a prospective single-blinded parallel control trial and will follow the principles of the Consolidated Standards of Reporting Trials (CONSORT). The study protocol was written in accordance with the Standard Protocol Items. Recommendations for Interventional Trails (SPIRIT) guidelines. Figure (Fig.) 1 is a sample of high-sustained pressure and alerting screens. The flowchart of the study design is shown in Fig. 2 and a detailed schedule of enrollment, intervention and assessment is given in Fig. 3. The trial is registered in the United States Clinical-trial.gov (NCTT05074849) on 29 September 2021.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eThis is a sample of high-sustained pressure alerting screens from the SurroSense RX smartwatch (Orpyx Medical Technologies Inc., Calgary, Canada). This sustained pressure could be because of the presence of a foreign object inside shoes that may remain unnoticed because of loss of protective plantar sensation in people with diabetes and neuropathy. When an alert is triggered, the user receives auditory, vibratory, and visual feedback from the watch. When the user acknowledges the alert, a map of each connected insoles is shown with the area of high-pressure alert identified in red [14].\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eStudy site\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eStudy sites include Baylor College of Medicine (BCM), Michael E. DeBakey VA Medical Center (MEDVAMC) and Texas Woman\u0026rsquo;s University (TWU) respectively. Many of our adult diabetic patients are seen at our various clinics (i.e., Endocrine and Primary Care at MEDVAMC and Division of Vascular and Endovascular Therapy and Interdisciplinary Consortium on Advanced Motion Performance (iCAMP) at BCM. Michael E. DeBakey Department of Surgery and BCM are the primary sites for recruitment. BCM is a unique environment for innovation. Researchers collaborate across institutions, creating a vast biomedical research ecosystem [44], building on over a century of leadership in biomedical research.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eParticipants\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe proposed study will recruit 72 patients, men and women, 18 years and above, ambulatory and have prescribed diabetic shoes seen in the clinics and centers around Houston, Texas. Individuals will be eligible for the trial if they meet the following inclusion criteria: (1)\u0026nbsp;History of diabetes\u0026nbsp;peripheral neuropathy (DFN)\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003ewith and without history\u0026nbsp;of peripheral artery disease (PAD); (2)\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003ehistory of foot ulcers within the last\u0026nbsp;6 months;\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e(3)\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003ewilling and able to\u0026nbsp;attend\u0026nbsp;follow up visits such as long\u0026nbsp;distance (i.e., greater than 30 miles\u0026nbsp;to recruitment\u0026nbsp;sites); (4)\u0026nbsp;able to read and follow\u0026nbsp;directions; and (5) those going through hemodialysis. However, individuals will not be enrolled into this trial if they meet the following exclusion criteria: (1) Active Charcot Arthropathy or major foot\u0026nbsp;deformity; (2)\u0026nbsp;wide spread malignancy or systemically\u0026nbsp;immunocompromising disease; (3) gangrene, active\u0026nbsp;infection; (4)\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003emajor amputation (above\u0026nbsp;ankle); (5) Mini Mental\u0026nbsp;Status-Examination (MMSE\u0026lt;20); (6)\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003eunable to keep research\u0026nbsp;appointments; (7)\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003eunable to walk safely a distance of 100\u0026nbsp;feet\u0026nbsp;with or without walking\u0026nbsp;assistance; (8)\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003ecardiopulmonary disease (e.g., recent MI,\u0026nbsp;Stroke); (9)\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003esignificant lower extremity edema which may limit the\u0026nbsp;participant from fitting into standard diabetic foot\u0026nbsp;wear;(10)\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003erefusal to\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003ewear prescribed diabetic\u0026nbsp;footwear; (11)\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003ethose with alcohol and drug abuse over the last 6\u0026nbsp;months; and (12)\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003esevere orthopedic and/or neuromuscular\u0026nbsp;impairments.\u0026nbsp;Individuals interested in the study will undergo a telephone interview by a\u0026nbsp;member of the research team.\u0026nbsp;Those meeting the\u0026nbsp;preliminary\u0026nbsp;inclusion\u0026nbsp;criteria\u0026nbsp;will\u0026nbsp;be\u0026nbsp;invited\u0026nbsp;to\u0026nbsp;discuss\u0026nbsp;their\u0026nbsp;potential\u0026nbsp;participation\u0026nbsp;in\u0026nbsp;details. During the screening visit, detailed information will be provided to study participants.\u0026nbsp;Verbal and written information of potential benefits and risks of the study will be provided; their questions\u0026nbsp;and concerns will be addressed. Written informed consent will be obtained by a trained researcher at the baseline visit. On the consent form, participants will be asked whether they agree to use their data when they withdraw from the trial and ask for permission for the research team to share their de-identify data with people from both universities taking part in the research or from the regulatory authorities.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eSample size calculation\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThis is a randomized control trial (RCT) study. The 63 participants will provide basic descriptive information on the various outcomes in the study (e.g., increased adherence to footwear, increased offloading, and decreased foot ulcers and improved foot self-care knowledge,). Sample size was estimated based on an initial study using a smart insole, conducted by Najafi et al. (Co- Investigator) [14]. In their study, the researchers observed that, in the group with at least one alert every 2 hours (high-alert group), adherence to footwear was improved and became significantly higher than in the low-alert group after 3 months of daily use of the technology (adherence to the prescribed footwear: 8.0\u0026plusmn;3.7 hours in the high-alert group v. 3.6\u0026plusmn;1.8 hours in the low-alert group, \u003cem\u003ep\u0026nbsp;\u003c/em\u003e= 0.035, Cohen\u0026rsquo;s effect size \u003cem\u003ed\u0026nbsp;\u003c/em\u003e= 1.37) indicating very large effect size. A \u003cem\u003epriori\u003c/em\u003e power analysis was conducted using Optimal Design 3.01. Based on a desired level of power set at 0.80, an alpha level of 0.05, and a more conservative large, standardized effect size of \u003cem\u003ed\u003c/em\u003e = 0.80, a minimum sample size of 63 is required for the 3 repeated measures on the primary outcome adherence to observe a significant difference between groups over time. With consideration of 10% drop out rate and the even sample size distribution among the 3 groups, a total of 72 (24 per group) are needed at the beginning of the study.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eRandomization and blinding\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eParticipants (72 participants) meeting the inclusion and exclusion criteria will be randomized (24 per group) into 3 groups: 1)\u0026nbsp;smart insoles + foot self-care education (Group 1); 2) smart insoles (Group 2); and 3) usual-care controls with no smart insoles\u0026nbsp;or education\u0026nbsp;(Group\u0026nbsp;3) using a software/random table. Study personnel will be instructed not to randomize until subjects have been confirmed to meet all the inclusion/exclusion criteria. An independent offsite investigator who is not involved in the enrollment or assessment of participants will be responsible for keeping the randomization schedule in sealed envelope. After the baseline assessment, the independent offsite investigator will open an opaque envelope sequentially and assign eligible participants to each group. Participants will be blinded to their allocated groups. Thus, this trial will be a single-blinded randomized control trial. Only the research team and the statistician will be aware of treatment allocation until the end of the study.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eStudy procedures\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eAll participants will be invited to attend the baseline visit and two-three other visits by participants in groups 1 and 2 respectively. Data at every visit will be collected in case report forms (CRFs) by the trial team. Research assistants (i.e., data collectors) will enter all data into a secure database. In the current trial and further ancillary studies, there are no plan for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eBaseline Visit\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eWhen the potential participants return for the baseline visit, the\u0026nbsp;research\u0026nbsp;staff\u0026nbsp;will\u0026nbsp;use\u0026nbsp;a scripted protocol to explain the study and the consent form. All questions raised by participants\u0026nbsp;will be addressed, and potential participants\u0026nbsp;will be invited to participate in the study. If an individual agrees,\u0026nbsp;a consent form will be obtained. The following will be performed: (1)\u0026nbsp;review the study with the subject and obtain written informed consent and Health Insurance Portability and Accountability Act of 1996 (HIPPA authorization); (2) assign subjects a unique screening/enrollment number; (3) review and record medical history, surgical history, and medication history to determine eligibility based on inclusion/exclusion criteria; (4) record demographics (age, race, ethnicity, gender); (5) document height, weight (Body Mass Index [BMI]), Blood glucose and Hemoglobin A1C; (6) document all current medications including medications over-the-counter and herbal medications; (7) perform foot examinations; and (8) administer screening questioners MMSE, Foot-Care Knowledge and Practice, Foot-Care Confidence Scale.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eData collection procedure\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eEvaluate the efficacy of smart insoles with real-time alert component +foot self-care education \u003cstrong\u003eH1\u003c/strong\u003e, to improve adherence to prescribed footwear and offloading in people with diabetes and at high risk for DFU. To achieve this hypothesis, Orthimeter (Germany) will tag patients\u0026rsquo; diabetic shoes. The system has 1-year battery life and enables continuous measuring adherence to footwear by measuring temperature. Adherence to footwear will be assessed every 2 months until 6 months or incidence of ulcers. Daily Adherence to Device Wear in hours (Sensor Data and Self-Report Questionnaire): participants will gather adherence data objectively using data recorded by the sensors and compared to subjective reports. The questionnaire will ask participants to estimate their wear time per day as 0-2 hours, 2-4 hours, 4-6 hours, 8-10 hours, or 10+ hours. To determine acceptability, ease of use, and perception of benefit, we will use a Technology Acceptable Model (TAM) tailored for the study.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eTAM\u0026nbsp;will\u0026nbsp;assess\u0026nbsp;users\u0026rsquo;\u0026nbsp;perception\u0026nbsp;of\u0026nbsp;benefits,\u0026nbsp;acceptability,\u0026nbsp;and\u0026nbsp;ease\u0026nbsp;of use with the wearable device.\u003csup\u003e\u0026nbsp;\u003c/sup\u003eParticipants will provide information on how strongly they agree or disagree with statements regarding benefits, acceptability, and ease of the wearable device on a 5-point scale with the following anchor: 1) strongly disagree, 2) somewhat disagree, 3) neutral, 4) somewhat agree, and 5) strongly agree. An average of four or higher indicates successful achievement on the TAM. We will also assess for the following: Foot Self-Care Knowledge and Practice, which has 15 questions on knowledge and 15 questions for practice. Cronbach\u0026rsquo;s alpha for the knowledge scale is 0.79, and practice is 0.72.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eDiabetes\u0026nbsp;Foot-Care\u0026nbsp;Behavior\u0026nbsp;Self-Efficacy\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe\u0026nbsp;Foot\u0026nbsp;Care\u0026nbsp;Confidence\u0026nbsp;Scale\u0026nbsp;will\u0026nbsp;be\u0026nbsp;used\u0026nbsp;to\u0026nbsp;test\u0026nbsp;foot\u0026nbsp;care self-efficacy.\u0026nbsp;Comprising\u0026nbsp;12\u0026nbsp;items,\u0026nbsp;with Cronbach\u0026rsquo;s\u0026nbsp;alpha\u0026nbsp;of\u0026nbsp;from\u0026nbsp;0.78\u0026nbsp;-\u0026nbsp;0.92.\u003csup\u003e\u0026nbsp;\u003c/sup\u003eOur assumptions are that \u003cstrong\u003eH1\u003c/strong\u003e: Participants randomized to the smart insole + foot self-care education group will be more adherent (as confirmed by sensor data and self-report questionnaire) to footwear and offloading after 6 months, compared to participants randomized to the smart insoles and usual-care groups. \u003cstrong\u003eH2:\u0026nbsp;\u003c/strong\u003eChanges\u0026nbsp;in\u0026nbsp;adherence\u0026nbsp;will\u0026nbsp;be\u0026nbsp;mediated\u0026nbsp;by\u0026nbsp;self-efficacy and\u0026nbsp;perception\u0026nbsp;of\u0026nbsp;benefits.\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003eSelf-efficacy will be assessed baseline and 6 months with the\u0026nbsp;Foot Care Confidence\u0026nbsp;Scale\u0026nbsp;(FCCS),\u0026nbsp;while perception of benefits will be assessed 2, 4, and 6 months with TAM.\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003eWhile TAM will test for perception of benefits.\u003cstrong\u003e\u0026nbsp;H3\u003c/strong\u003e: Participants randomized to the smart insole + foot self-care education group will have higher acceptability and perception (as confirmed by TAM) of the benefits of their intervention, compared to those randomized to the smart insoles only and\u0026nbsp;usual-care control groups.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eFollow-up visits\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThere will be a biweekly visits in the first month, 2, 4, and 6 months, 30-minute one-on-one follow-up phone discussion (i.e., daily foot hygiene and cleanliness, foot protection, use of insoles and smart watch, adverse effects, addressing feedback and questions regarding the intervention and prevention of foot-related complications) on participants in \u0026nbsp;groups 1 and 2. Participants in groups 1 and 2 will also return for a group visit within 1-3 weeks post baseline for intervention (group 1 receiving both foot self-care foot education as well as insoles fitting on their diabetic shoes as well as the smart watch while group 2 will only receive only insoles on their diabetic shoes and smart watch). Participants in groups 1 and 2 will be followed for additional 2, 4, and 6 months to assess for daily adherence of device wear, successful response rate to alert and duration, user perception of benefits, acceptability, and ease of use of device among others. While participants in group 3 will be followed for 2, 4, and 6 months. At 6 months, all participants including those in the usual care group 3 will return for the following: (1) assess adverse effects;\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e(2)\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003eassess for complications following treatments; (3) document current medications including over-the-counter and herbal medications; (4) perform foot examinations and document any foot ulcers \u0026nbsp;or complications; (5) document height, weight (Body Mass Index [BMI]); (6) blood glucose and Hemoglobin A1C; and (7) administer screening questioners (Foot-Care Knowledge and Practice, Foot-Care Confidence Scale, TAM, Research Activity Log, Sensor Data and Self-Report and Successful Response rate to Alert and Unresponded Alert Duration).\u003c/p\u003e\n\u003cp\u003eAt each visit, if participants make a withdrawal request or are not eligible to continue due to the presence of severe concomitant diseases or conditions listed in the exclusion criteria, they will be discontinued from the study. For participants who drop out, the following information including the incidence of foot ulcer; footwear and offloading adherence, plantar pressures (if possible), as well as administer study questionnaires (Foot-Care Knowledge and Practice, Foot-Care Confidence Scale) will be collected. All subjects are free to withdraw from participation at any time, for any reason, specified or unspecified, and without prejudice. Reasonable attempts will be made by the investigator to provide a reason for subject withdrawals. The reason for the subject\u0026rsquo;s withdrawal from the study will be specified in the subject\u0026rsquo;s source documents and workbook on foot-care strategies\u0026nbsp;and pamphlets for self-guidance. If a subject is withdrawn due to adverse effects (such as diabetic ulcers), the subject will be followed and treated by the investigators until the abnormal parameter of symptoms has resolved or stabilized. The investigators must make every effort to contact subjects who are lost to follow-up. Attempts to contact such subjects must be documented in the subject\u0026rsquo;s records (e.g., times and dates of attempted telephone contact, receipt for sending a registered letter, etc.).\u003c/p\u003e\n\u003cp\u003eTo improve participants\u0026rsquo; retention and complete follow-up, the following measures will be adopted: participants\u0026rsquo; contact information as well as contact information for at least two persons who would know the participants\u0026rsquo; whereabouts and could get messages to them; assign a \u0026ldquo;coach\u0026rdquo; from the team who will\u0026nbsp;develop relationships,\u0026nbsp;reinforce participation, and help overcome barriers that can lead to study withdrawal; and compensate for\u0026nbsp;study-related\u0026nbsp;visits at $50 for each visit.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eInterventions\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eA 6-month intervention consisting of (\u003cstrong\u003eBaseline: Weeks 1-3\u003c/strong\u003e): 1) contacting prospective participants, 2) screening, 3) completing informed consent, and 4) randomization. \u003cstrong\u003eWeek 4\u003c/strong\u003e: A 90-minute group session to educate patients on foot self-care strategies (daily foot hygiene and cleanliness, foot protection, use of insoles and smart watch). Participants (72 participants) will be randomized (24 per group) into 3 groups: 1) smart insoles + education (Group 1); 2) smart insoles (Group 2); and 3) usual-care controls with no smart insoles or education (Group 3).\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eInsoles with Smart Watches\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eSmart insole with an alert watch\u0026nbsp;(the SurroSense RX system, Orpyx Medical Technologies, Inc., Calgary, Ca, Fig. 1) [14],\u003csup\u003e\u0026nbsp;\u003c/sup\u003eis for cuing plantar\u0026nbsp;pressure offloading during activities of daily living [14].\u0026nbsp;Each insole consists of eight individual pressure sensors: three distributed across the metatarsal heads, two distributed along the lateral plantar surface, and one distributed at the heel,\u0026nbsp;one distributed at the great toe, and one in the distribution of the lateral toes. [14].\u0026nbsp;The insoles collect\u0026nbsp;pressure information from the plantar surface of the foot and wirelessly transmit this information to the\u0026nbsp;smart watch worn by participants. The device alerts the user when \u0026ldquo;safe\u0026rdquo; pressure and time thresholds are\u0026nbsp;exceeded [14].\u0026nbsp;These thresholds are based on the clinical understanding of pressure ulcer formation, which indicates that\u0026nbsp;a conservative threshold would be \u0026gt;35-50 mmHg for \u0026gt;15 minutes. If \u0026gt; 95% of measurements taken by a\u0026nbsp;single sensor over a 15-minute scanning window exceed 35-50 mmHg, an alert will be sent to the user via\u0026nbsp;the smart watch to guide him/her to appropriately offload that area. A\u0026nbsp;successful response to an alert is defined as\u0026nbsp;a pressure offloading occurring within 20 minutes of alert onset [14].\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eFoot Self-Care Education\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eContents for the foot self-care education are adapted from standard diabetes organization [2, 39-42], comprising information (i.e., risk factors of diabetes foot complications, foot self-examination, daily foot hygiene and cleanliness, foot protection, prevention of foot-related complications, and need for an annual evaluation by a healthcare professional) [2, 39-42]. A foot-care package, consisting of a pamphlet on foot self-care, a nail clipper, a water-based lotion, and a small towel will be provided to each participant.\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eParticipation in Group Education Program and Follow-up Telephone Calls\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eA 90-minute group educational session will be conducted once in person in a conference room at the study centers. The educational session will cover foot-care strategies (i.e., risk factors of diabetes foot complications, foot self-examination, daily foot hygiene and cleanliness, foot protection, prevention of foot- related complications, benefits of wearing prescribed diabetic footwear, using smart insole with smart watch, and need for an annual evaluation by a healthcare professional) [2, 38-41]. A call will be conducted every 2 weeks to follow-up on participants\u0026rsquo; progress and address concerns for groups 1 and 2. Participants will be advised to call the research staff with questions and concerns at any time.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eParticipants\u0026rsquo; Information\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eEach participant in group 1 will receive\u0026nbsp;a workbook on foot-care strategies\u0026nbsp;and pamphlets for self-guidance. In addition, all participants in each group will receive a foot care package (i.e., pamphlet, nail clipper, water-based lotion, and small towel) [42]. Participants are expected to\u0026nbsp;keep the workbook, pamphlet, and foot-care package at the end of the study.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eOutcome measures\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003ePrimary Outcomes\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003ePrimary outcome measures\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003eare adherent to footwear and offloading. To\u0026nbsp;objectively\u0026nbsp;monitor\u0026nbsp;adherence\u0026nbsp;to\u0026nbsp;the\u0026nbsp;prescribed\u0026nbsp;shoes,\u0026nbsp;participants\u0026rsquo;\u0026nbsp;shoes\u0026nbsp;will be tagged by a miniaturized temperature + a radio-frequency identification (RFID) sensor named Orthimeter (Germany).\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003eThe pressure sensing device is equipped\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003ewith audio-visual alerts and offloading instructions when sustained elevated pressures are detected. The system enables continuous monitoring of the individual\u0026rsquo;s adherence to wearing the prescribed diabetic footwear.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eSecondary Outcomes\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eSecondary outcome measures are\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003eincidence of diabetic foot ulcers (DFUs) measured by self-report and foot examinations by the podiatrist and study team. DFU is defined as a full-thickness wound, through the dermis, below the ankle on weight-bearing or exposed surface in an individual with diabetes [67]. We will also monitor for improved foot self-care knowledge and Practice with Foot Self-Care Knowledge and Practice baseline and at 6 months.\u0026nbsp;Foot Self-Care\u0026nbsp;Knowledge and Practice\u0026nbsp;has 15 questions on knowledge and 15 questions for practice. Cronbach\u0026rsquo;s\u0026nbsp;alpha\u0026nbsp;for\u0026nbsp;the\u0026nbsp;knowledge\u0026nbsp;scale\u0026nbsp;is\u0026nbsp;0.79,\u0026nbsp;and\u0026nbsp;practice\u0026nbsp;is\u0026nbsp;0.72 [45, 46].\u0026nbsp;In addition, we will monitor for daily adherence to device wear in hours and off-loading at 2, 4, and 6 months with the sensor data and self-report. To enhance retention and compliance, participants will\u0026nbsp;undergo\u0026nbsp;a\u0026nbsp;detailed\u0026nbsp;orientation\u0026nbsp;and\u0026nbsp;cognitive\u0026nbsp;evaluation\u0026nbsp;(e.g.,\u0026nbsp;Mini Mental State Examination [MMSE]) [49].\u0026nbsp;A score of MMSE \u0026lt;20 indicates mild degree of impairment and participants will not be enrolled in the study [49]. Perception of benefit, acceptability, and ease of use measured by the TAM [14].\u0026nbsp;Participants will provide information on how strongly they agree or disagree\u0026nbsp;with statements regarding benefits, acceptability, and ease of the wearable device on a 5-point scale with\u0026nbsp;the following anchor: 1) strongly disagree, 2) somewhat disagree, 3) neutral, 4) somewhat agree, and 5)\u0026nbsp;strongly agree. An average of 4 or higher indicates successful achievement on the TAM [14].\u0026nbsp;A\u0026nbsp;mediation outcome\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003eself-efficacy will be assessed at baseline and 6 months by the Foot Self-Care Knowledge and Practice [46, 47] and Diabetes Foot-Care Behavior Self-Efficacy [47, 48]. Our assumptions are that \u003cstrong\u003eH1\u003c/strong\u003e: Participants randomized to the smart insole + foot self-care education group will be more adherent (as confirmed by sensor data and self-report questionnaire) to footwear after 6 months, compared to participants randomized to in the smart insoles and usual-care groups. \u003cstrong\u003eH2:\u0026nbsp;\u003c/strong\u003eChanges\u0026nbsp;in\u0026nbsp;adherence\u0026nbsp;will\u0026nbsp;be\u0026nbsp;mediated\u0026nbsp;by\u0026nbsp;self-efficacy and\u0026nbsp;perception\u0026nbsp;of\u0026nbsp;benefit.\u0026nbsp;The Foot Care Confidence\u0026nbsp;Scale\u0026nbsp;will assess for self-efficacy; a 12 items scale with a Cronbach\u0026rsquo;s of from\u0026nbsp;0.78 -\u0026nbsp;0.92 in those with diabetes who monitored for foot\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003eulcer [48]. While TAM will test for perception of benefits.\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003cstrong\u003eH3\u003c/strong\u003e: Participants randomized to the smart insole + foot self-care education group will have higher acceptability and perception (as confirmed by TAM) of the benefits of their intervention, compared to those randomized to the smart insoles only and usual-care control groups.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eDemographics and clinical indicators\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eParticipants\u0026rsquo; characteristic of age, weight, body mass index, current medication issues, current medications, diabetes history, other chronic diseases such as high blood pressure, periphery artery diseases, neuropathy will be collected using electronic case report forms. Participants will be asked for number and types of medications taken, medication scheduling, and the dose used to self-manage diabetes as well as DFU symptoms at baseline and at 6 months.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eData management\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eData monitoring\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eAll researchers including investigators, data collectors (i.e., research assistants), study coordinators, site monitors, data managers, outcome assessors, and statistician will receive special training regarding the standard procedure and data management. The Principal Investigator will be responsible to ensure the study is conducted in accordance with the protocol, Good Clinical Practice (GCP), applicable regulatory requirements, and that the data recorded is valid. To achieve this objective, the study will be continuously monitored and reviewed in a monthly basis by the study team.\u003c/p\u003e\n\u003cp\u003eClinical site monitoring is conducted to ensure that the rights and well-being of human subjects are protected, that the reported trial data are accurate, complete, and verifiable, and that the conduct of the trial complies with the currently approved protocol/amendment(s) with GCP, and with applicable regulatory requirements(s). A Clinical Monitoring Plan will be created by the Sponsor and describe in details as well as who will conduct the monitoring, and the distribution of monitoring reports.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eData handling and record keeping\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003ecollection of personal patient information will be limited to the amount necessary to achieve the aims on the research, so that no unneeded sensitive information is being collected. Only study personnel will collect data. Hard copy documents will be retained for the duration of the study until data entry and will be saved for at least 5 years after publication. All hard copy documents related to the research will be saved in a locked filling cabinet of GCP at MEDVAC/BCM, while electronic documents will be stored in a special computer with protected password. Data will be exported into the Excel or SAS file format (password protected), which will then be used for data analysis. Only de-identified data will be used for data analysis. Collected de-identified data will be sent to a biostatistician for statistical analysis. If readers have any questions about our published data, they could contact our corresponding author (i.e., the principal investigator) to obtain the original data.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eStatistical Analysis\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eAt the end of this trial, all original data without participants\u0026rsquo; name and the random sequences will be sent to a statistician for data analysis. Data will be downloaded from each smart watch and analyzed, using SPSS (IBM, version 25, Chicago IL) and MPlus v7.3 [68]. To identify possible predictors of adherence rates, participants will be categorized, based on whether they responded to alert or not (HA: high-alert group) or less (LA: low-alert group) defined as one alert every 2 hours that the device is worn. Intent-to-treat procedures will be used to treat the missing data on the outcomes for Aim 1-H1. Results will be expressed as means \u0026plusmn; standard deviation (SD). Repeated measures ANOVA will be used to compare adherences among the three groups at 2 months and 6 months. If overall significance is found, post hoc comparison using Tukey\u0026rsquo;s test will be used to examine the adherence difference between every two groups. If assumption of homogeneity of variables is violated Games-Howell post hoc test will be used instead. Pearson\u0026rsquo;s correlation analysis will be used to examine correlation between changes in adherence over 2 months to 6 months and number of alerts triggered per hour in each group. Cohen\u0026rsquo;s \u003cem\u003ed\u0026nbsp;\u003c/em\u003eeffect size will be used to estimate mean- difference effect sizes between groups. Cohen\u0026rsquo;s \u003cem\u003ed\u0026nbsp;\u003c/em\u003evalue of 0.2, 0.5, and 0.8 will be considered small,\u0026nbsp;medium, and large effect sizes, respectively [14, 50].\u003csup\u003e\u0026nbsp;\u003c/sup\u003eLatent growth curve mediation model\u0026nbsp;will be used to test the effect of the\u003cem\u003e\u0026nbsp;\u003c/em\u003ecombined smart insole and foot self-care education on improving adherence to footwear at every 2 months till 6 months, in which time points will be used as repeated measures, baseline demographics and treatment will be included as first level fixed effect, participants will be as second level random effect, and perception/self-efficacy will be the third level random effect\u003cem\u003e.\u0026nbsp;\u003c/em\u003eMixed models accommodate the longitudinal design with random effects; allow for testing differences between groups in patterns over time as well as at specific time points;, and are valid for data which are missing completely at random or at random (2). Latent growth models are particularly used in the mediation analysis to examine the individual trajectory change over 6 months of period and that a relatively large intra-individual change is anticipated. All statistical analyses will be performed using SPSS (IBM, version 25, Chicago IL) and MPlus v7.31, with a significance level of \u003cem\u003eP\u003c/em\u003e \u0026lt; .05.\u003c/p\u003e"},{"header":"Discussion","content":"\u003cp\u003eOver the years, well-designed RCTs have failed to produce outcomes in terms of preventing initial and recurrent DFU in individuals at risk for DFU. Previous studies show that adherence to prescribed diabetic footwear and offloading harmful plantar pressures are critical in preventing DFU in at risk individuals (i.e., those with peripheral neuropathy, PAD). The question remains why these diabetic foot wears or the numerous offloading devices (i.e., smart insoles with alert device) among others recommended for patients are not addressing the overwhelming incidences of DFU seen in individuals at high risk for DFU. A lower-limb amputation due to diabetes occurs every 20 seconds, of which 85% are preceded by foot ulceration [68]. Diabetic footwear is recommended for all patients at risk for diabetes foot ulcers. Diabetic footwear decreases incidence of DFUs and reulceration. While offloading harmful pressure areas that can lead to DFU is gaining momentum about preventing DFU in at risk individuals with diabetes. There is evidence that elevated plantar pressure contributes to the development of DFU, which makes relief of mechanical pressure (also called offloading) a recommended approach. A recent study by Najafi and colleagues demonstrated the efficacy and feasibility of smart insoles with real-time alerts for plantar pressure offloading in those at-risk individuals with DFU. The smart-insole device was designed to cue offloading to manage unprotected sustained plantar pressures to prevent foot ulceration. Interestingly, their study suggested that, in the group with at least one alert every 2 hours, adherence to prescribed footwear was increased or retained over time, whereas a lower number of alerts reduced adherence. The authors speculated that reduced adherence in the low-alert group may be linked to disengagement or reduced perception of benefit. It is unknown whether smart insoles with alerts improve use of footwear, offloading, and lower the incidence of DFU, compared to usual care. It is unknown whether self-efficacy will mediate performance accomplishments (use of smart insoles+ smart watch) behavior performance (wearing diabetic shoes) and desired outcomes (improve adherence to diabetic footwear, improve offloading and reduce incidence of foot ulcers) in those at risk for DFU.\u003c/p\u003e \u003cp\u003eIn the present study, we are proposing a RCT to assess whether a modern technology (i.e., alert-base insoles plantar offloading device) plus foot self-care education will improve adherence to prescribed footwear, improve offloading harmful foot pressure areas, and reduce the incidence of DFU in those at-risk individuals with diabetes. As a multifaceted intervention, we speculate the proposed intervention has the potential to: 1) increase adherence and increase perception of benefit of prescribed footwear; 2) release individuals from the substantial burden of having to endure countless DFUs as a result of having diabetes; 3) raise awareness and knowledge of early intervention to prevent DFU, which, in turn, will prevent severe and costly outcomes in diabetes care; 4) provide information that can potentially advance the way DFU is managed in clinical practice; and 5) provide valuable preliminary knowledge to guide future research on the use of technology for an optimal preventive approach to prevent initial and recurrent DFU in at -risk individuals with diabetes. At the end of this trial, we will compare the results from this study with previous RCTs about adherence to prescribed footwear and offloading devices in the prevention of DFU.\u003c/p\u003e \u003cp\u003eResult from previous studies show that these sustained high plantar pressures are managed through passive methods, such as orthotics, medical arch support, Rocker shoes, and custom insoles, which are not effective in reducing pressure in certain areas of the foot [14, 24]. Due to the passivity of these devices, users are limited to physically altering the architecture of the foot and are not encouraged to adjust their behavior by offloading harmful pressure areas [14]. Studies show that proper prevention of foot ulcers should consider the importance of foot biomechanics and patient behavior [2]. The current standard of care for preventing foot ulcers includes screening for foot ulcers, risk classification, regular foot care, protective shoes and insoles, and diabetic foot education [14, 33]. Increasingly, studies have begun to use feedback devices to help at risk populations avoid negative outcomes [14, 34, 35]. The smart insole with an alert technology we are proposing is designed with sensors that monitor continuous plantar pressure and provide the user with alert-based feedback when plantar pressures are too high [14, 36]. It has been determined, however, that this smart insole, together with an alert-based feedback system, (a) successfully notified patients of harmful pressures (b) has been proven to be effective and acceptable by high-risk diabetic patients, and (c) may enhance adherence to prescribed footwear.\u003c/p\u003e \u003cp\u003eAdherence to diabetic footwear and prevention of foot ulcers in patients with diabetes will require an integrated approach of patient education on foot self-care and wearing therapeutic or prescribed footwear [3]. Adherence to a treatment regime is confirmed to play a key role in clinical outcome [3, 13, 30]. Interventions targeting those with diabetes and at risk for DFUs are urgently needed to help clinicians treating patients with diabetes. Previous integrated approaches do not involve state-of-the art interventions or specific knowledge about factors that increase sustained adherence to footwear, prevention, or prediction of DFU recurrence [3]. Our proposed study is an integrated approach that will not only address ways to improve sustained adherence to footwear, but also potentially prevent initial appearance and recurrence of foot ulcer. Education alone does not improve the use of diabetic footwear and diabetes foot self-care behaviors [6, 11]. Although education aiming to promote foot self-care to prevent foot lesions has been widely advocated and implemented in standard practice, evidence for the effectiveness in improving sustained adherence to prescribed footwear and prevention of foot ulcer is still scarce [6]. Patient education has different methods (e.g., individual or group sessions), different length of treatment (e.g., single, or weekly sessions), different educators (e.g., nurses, podiatrists, physicians) and different delivery methods (e.g., video chat, telephone) [13]. The most beneficial patient education that can lead to sustained adherence to prescribed footwear in at-risk individuals with diabetes has yet to be investigated [13]. Many educational interventions of foot self-care focus primarily on improving self-management behavior [9, 13, 31, 32], which is beneficial, but lacks evidence within the scope of sustained adherence to prescribe footwear and foot-ulcer prevention [13]. The current proposal represents an unprecedented opportunity to support the hypothesis that an integration of alert-based insoles for plantar pressure offloading and foot self-care education will result in increased and sustained adherence to prescribed diabetes footwear, improve offloading of harmful pressure foot areas and will, ultimately, prevent future DFUs [3].\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eEthics and Dissemination\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe study will be completed in accordance with the ethical principles in the Declaration of Helsinki and the International Conference on Harmonization (ICH) GCP Guideline. Texas Woman’s University and Baylor College of Medicine will be primary sites for the study and will monitor and audit this project to ensure compliance with the necessary legislation. The protocol, informed consent form(s), and all pertinent data collection materials were submitted to the IRB for review and prior approval. This is a low-risk trial because therapeutic footwear and smart insoles with a smart watch are non-invasive and will be delivered by a trained, registered podiatrist, nurse, or vascular surgeon. Any adverse events will be recorded by investigators and reported to the trial team. Participants will also be offered the opportunity to report any adverse events at follow-up assessments.\u003c/p\u003e\n\u003cp\u003eAt the end of the trial, we will present our findings at the national and international conferences and peer reviewed nursing and medicine journals.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eTrial Status\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThis protocol was approved 15 September 2021. Recruitment of participants will commence approximately in July 2022. Recruitment will be stopped automatically as soon as 72 participants have been included, which will be completed approximately July 2024.\u003c/p\u003e"},{"header":"Abbreviations","content":"\u003cdiv class=\"DefinitionList\"\u003e \u003cdiv class=\"DefinitionListEntry\"\u003e \u003cdiv class=\"Term\"\u003eDFU\u003c/div\u003e \u003cdiv class=\"Description\"\u003e \u003cp\u003eDiabetic foot ulcer\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003cdiv class=\"DefinitionListEntry\"\u003e \u003cdiv class=\"Term\"\u003eED\u003c/div\u003e \u003cdiv class=\"Description\"\u003e \u003cp\u003eEmergency room\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003cdiv class=\"DefinitionListEntry\"\u003e \u003cdiv class=\"Term\"\u003eBCM\u003c/div\u003e \u003cdiv class=\"Description\"\u003e \u003cp\u003eBaylor College of Medicine\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003cdiv class=\"DefinitionListEntry\"\u003e \u003cdiv class=\"Term\"\u003eMEDVAMC\u003c/div\u003e \u003cdiv class=\"Description\"\u003e \u003cp\u003eMichael E. DeBakey VA Medical Center\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003cdiv class=\"DefinitionListEntry\"\u003e \u003cdiv class=\"Term\"\u003eTWU\u003c/div\u003e \u003cdiv class=\"Description\"\u003e \u003cp\u003eTexas Woman\u0026rsquo;s University\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003cdiv class=\"DefinitionListEntry\"\u003e \u003cdiv class=\"Term\"\u003eCONSORT\u003c/div\u003e \u003cdiv class=\"Description\"\u003e \u003cp\u003eConsolidated Standards of Reporting Trials\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003cdiv class=\"DefinitionListEntry\"\u003e \u003cdiv class=\"Term\"\u003eSPIRIT\u003c/div\u003e \u003cdiv class=\"Description\"\u003e \u003cp\u003eiCAMP:Interdisciplinary Consortium on Advanced Motion Performance\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003cdiv class=\"DefinitionListEntry\"\u003e \u003cdiv class=\"Term\"\u003eDFN\u003c/div\u003e \u003cdiv class=\"Description\"\u003e \u003cp\u003eDiabetes peripheral neuropathy\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003cdiv class=\"DefinitionListEntry\"\u003e \u003cdiv class=\"Term\"\u003ePAD\u003c/div\u003e \u003cdiv class=\"Description\"\u003e \u003cp\u003ePeripheral artery disease\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003cdiv class=\"DefinitionListEntry\"\u003e \u003cdiv class=\"Term\"\u003eMOCA\u003c/div\u003e \u003cdiv class=\"Description\"\u003e \u003cp\u003eMontreal Cognitive Assessment\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003cdiv class=\"DefinitionListEntry\"\u003e \u003cdiv class=\"Term\"\u003eRCT\u003c/div\u003e \u003cdiv class=\"Description\"\u003e \u003cp\u003eRandomized Clinical Trials\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003cdiv class=\"DefinitionListEntry\"\u003e \u003cdiv class=\"Term\"\u003eCRF\u003c/div\u003e \u003cdiv class=\"Description\"\u003e \u003cp\u003eH:Hypothesis\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003cdiv class=\"DefinitionListEntry\"\u003e \u003cdiv class=\"Term\"\u003eTAM\u003c/div\u003e \u003cdiv class=\"Description\"\u003e \u003cp\u003eTechnology Acceptable Model\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003cdiv class=\"DefinitionListEntry\"\u003e \u003cdiv class=\"Term\"\u003eBMI\u003c/div\u003e \u003cdiv class=\"Description\"\u003e \u003cp\u003eBody Mass Index\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003cdiv class=\"DefinitionListEntry\"\u003e \u003cdiv class=\"Term\"\u003eLA\u003c/div\u003e \u003cdiv class=\"Description\"\u003e \u003cp\u003eLow-Alert\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003cdiv class=\"DefinitionListEntry\"\u003e \u003cdiv class=\"Term\"\u003eGCP\u003c/div\u003e \u003cdiv class=\"Description\"\u003e \u003cp\u003eGood Clinical Practice\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003cdiv class=\"DefinitionListEntry\"\u003e \u003cdiv class=\"Term\"\u003eSD\u003c/div\u003e \u003cdiv class=\"Description\"\u003e \u003cp\u003eStandard Deviation\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003cdiv class=\"DefinitionListEntry\"\u003e \u003cdiv class=\"Term\"\u003eIBM\u003c/div\u003e \u003cdiv class=\"Description\"\u003e \u003cp\u003eInternational Business Machines Corporation\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003cdiv class=\"DefinitionListEntry\"\u003e \u003cdiv class=\"Term\"\u003eICH\u003c/div\u003e \u003cdiv class=\"Description\"\u003e \u003cp\u003eInternational Conference on Harmonization\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003cdiv class=\"DefinitionListEntry\"\u003e \u003cdiv class=\"Term\"\u003eIRB\u003c/div\u003e \u003cdiv class=\"Description\"\u003e \u003cp\u003eHIPPA:Health Insurance Portability and Accountability\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003c/div\u003e"},{"header":"Declarations","content":"\u003cp\u003e\u003cstrong\u003eAcknowledgements\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eWe thank Dr. Madhura and Ms. Lindsey for their support as investigator wrote the proposal.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAuthors’ contributions\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe authors’ responsibilities were as follows: NDM and BN designed the study. NMD conducted the systematic review including the foot self-care education and intervention. WW completed the sample size calculations and constructed the randomization and data analysis. All authors critically appraised the protocol and approved the final manuscript.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eFunding\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThis study is funded and sponsored in part by the Texas woman’s University (Support research) and\u0026nbsp;\u003cstrong\u003eCOMRADE Grant # R25NS094093-02.\u003c/strong\u003eThe sponsor has not taken part in the study design.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAvailability of data and material\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eNot applicable\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eEthics approval and consent to participate\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eEthics approval was obtained from the Texas Woman’s University Institutional Review Board (IRB) in Houston Campus, Texas-United States.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eConsent for publication\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eNot applicable\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompeting interests\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe authors have no relevant afflictions or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject, matter or matters discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants, or patients received or pending, or royalties.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAuthors’ information\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eNDM, PhD, Assistant Professor, Texas Woman’s University, Nelda C. Stark, College of Nursing 6700 Fannin Street Houston, TX 77030. United States. WW, PhD, Statistician Texas Woman’s University, Center for Research Design and Analysis, Office of Research and Sponsored Programs. 6700 Fannin Street Houston, TX 77030. United States. Bijan Najafi, PhD, Professor of Surgery, Director of Clinical Research at Division of Vascular Surgery and Endovascular Therapy, Michael E. DeBakey Department of Surgery, Baylor College of Medicine and Director of Interdisciplinary Consortium on Advanced Motion Performance (iCAMP), McNair Campus, Houston, Texas-United States.\u003c/p\u003e"},{"header":"References","content":"\u003col\u003e\n \u003cli\u003eMaciejewski ML, Reiber GE, Smith DG, Wallace C, Hayes S. Effectiveness of diabetic therapeutic footwear in preventing reulceration. \u003cem\u003eDiabetes Care\u003c/em\u003e. 2004;27(7):1774-1782.\u003c/li\u003e\n \u003cli\u003eBus SA, van Netten JJ, Lavery LA, Monteiro-Soares M, Rasmussen A, Jubiz Y, et al. IWGDF Guidance on the prevention of foot ulcers in at-risk patients with diabetes. International Working Group on the Diabetic Foot. 2016. http://www.d-foot.org/d-foot/wpcontent/uploads/_PDF/RESOURCES/Guideline%20Prevention.pdf. Accessed 20 Jan 2020.\u003c/li\u003e\n \u003cli\u003eArmstrong DG, Boulton AJM, Bus SA. Diabetic foot ulcers and their recurrence. \u003cem\u003eN Engl J Med\u003c/em\u003e. 2017;376(24):2367-2375. doi:10.1056/NEJMra1615439.\u0026nbsp;\u003c/li\u003e\n \u003cli\u003eFan L, Sidani S, Cooper-Braithwaite A. Feasibility, acceptability, and effects of a foot self-care education intervention on minor foot problems in adult patients with diabetes at low risk for foot ulceration: A pilot study. \u003cem\u003eCan J Diabetes\u003c/em\u003e.\u003cem\u003e\u0026nbsp;\u003c/em\u003e2013;37(2013):195-201.\u003c/li\u003e\n \u003cli\u003e\u0026nbsp;Prompers L, Huijberts M, Apelqvist J, et al. High prevalence of ischemia, infection, and serious comorbidity inpatients with diabetic foot disease in Europe. Baseline results from the Eurodiale study. \u003cem\u003eDiabetologia\u003c/em\u003e.\u003cem\u003e\u0026nbsp;\u003c/em\u003e2007; 50:18-25. doi:10.1007/s00125-006-0491-1.\u003c/li\u003e\n \u003cli\u003eFrykberg RG, Lavery LA, Pham H, Harkless L, Veves A. Role of neuropathy and high foot pressures in diabetic foot ulceration. \u003cem\u003eDiabetes Care\u003c/em\u003e.\u0026nbsp;1998;21(10):1714-1719.\u003c/li\u003e\n \u003cli\u003eDorresteijn JAN, Kriegsman DMW, Assendelft WJJ, Valk GD. Patient education for preventing diabetic foot ulceration (Review). \u003cem\u003eCochrane Database Syst Rev\u003c/em\u003e.\u003cem\u003e\u0026nbsp;\u003c/em\u003e2014;12(CD001488):1-53. doi: 10.1002/14651858.CD001488.pub5.\u003c/li\u003e\n \u003cli\u003eUnwin N. Epidemiology of lower extremity amputation in centres in Europe, North America, and East Asia: The Global Lower Extremity Amputation Study Group. \u003cem\u003eBr J Surg\u003c/em\u003e.\u003cem\u003e\u0026nbsp;\u003c/em\u003e2000; 87:328-337.\u003c/li\u003e\n \u003cli\u003ePecoraro RE, Reiber GE, Burgess EM. Pathways to diabetic limb amputation. Basis for\u0026nbsp;prevention.\u003cem\u003e\u0026nbsp;Diabetes Care\u003c/em\u003e.\u003cem\u003e\u0026nbsp;\u003c/em\u003e1990;13(5):513-521. doi:10.2337/diacare.13.5.513.\u003c/li\u003e\n \u003cli\u003eCorbett Cf. A randomized pilot study of improving foot care in home health patients with diabetes. \u003cem\u003eDiabetes Educ\u003c/em\u003e.\u003cem\u003e\u0026nbsp;\u003c/em\u003e2003; 29:273-282. doi:10.1177/014572170302900218.\u003c/li\u003e\n \u003cli\u003eDorresteijn JAN, Kriegsman DMW, Assendelft WJJ, Valk GD. Patient education for preventing diabetic foot ulceration (review). \u003cem\u003eThe Cochran Library\u003c/em\u003e. 2012; 10:1-51.\u003c/li\u003e\n \u003cli\u003eSchaper NC, Van Netten JJ, Apelqvist J, et al. Prevention and management of foot problems in diabetes. A summary guidance for daily practice based on the 2015 IWGDF Guidance Documents. \u003cem\u003eDiab\u003c/em\u003e \u003cem\u003eMetab Res Rev\u003c/em\u003e.\u003cem\u003e\u0026nbsp;\u003c/em\u003e2016;32(Suppl 1):7-15.\u0026nbsp;doi:10.1002dmrr.2695.\u003c/li\u003e\n \u003cli\u003evan Netten JJ, Price PE, Lavery LA, et al. Prevention of foot ulcers in the at-risk patient with diabetes: A systematic review. \u003cem\u003eDiabetes Metab Res Rev\u003c/em\u003e.\u003cem\u003e\u0026nbsp;\u003c/em\u003e2016;32(1):84-98. doi:10.1002/dmrr.2701.\u003c/li\u003e\n \u003cli\u003e\u0026nbsp;Najafi B, Ron E, Enriquez A, Marin I, Razjouyan J, Armstrong DG. Smarter sole survival: Will neuropathic patients at high risk for ulceration use a smarter insole-based foot protection system? \u003cem\u003eJ Diabetes Sci Technol\u003c/em\u003e. 2017;11(4):702-713. doi:10.1177/1932296816689105.\u003c/li\u003e\n \u003cli\u003eBoulton, AJM, Whitehouse RW. The Diabetic Foot. [Updated 2020 Mar 15]. In: Feingold KR, Anawalt B, Boyce A. et al., editors [Internet]. South Darmouth (MA): MDText.com, Inc.; 200-, https://www.ncbi.nlm.nih.gov/books/NBK409609/. Accessed 12 Nov 2021.\u003c/li\u003e\n \u003cli\u003eKerr M, Rayman G, Jeffcoate WJ. Cost of diabetic foot disease to the National Health Service in England. \u003cem\u003eDiab Med\u003c/em\u003e. 2014;31(12):1498-1504.\u0026nbsp;doi:10.1111/dme.12545.\u003c/li\u003e\n \u003cli\u003eThewjitchatoen Y, Sripatpong J, Krittiyawong S. et al. Changing the patterns of hospitalized diabetic foot ulcer (DFU) over a 5-year period in a multi-disciplinary setting in Thailand. \u003cem\u003eBMC Endocr Disord\u003c/em\u003e 2020; 89. \u003ca href=\"https://doi.org/10.1186/s12902-020-00568-7\"\u003ehttps://doi.org/10.1186/s12902-020-00568-7\u003c/a\u003e.\u003c/li\u003e\n \u003cli\u003eZhang P, Lu J, Tang S, Zhu D, Bi Y. Global epidemiology of diabetic foot ulceration: A systematic review and meta-analysis. \u003cem\u003eAnn Med\u003c/em\u003e. 2017;49(2):106-116. doi:10.1080/07853890.2016.1231932.\u0026nbsp;\u003c/li\u003e\n \u003cli\u003eTennvail GR, Apelqvist J. Health-economic consequences of diabetic foot lesions. \u003cem\u003eClin Infect Dis\u003c/em\u003e.\u003cem\u003e\u0026nbsp;\u003c/em\u003e2004;39(Suppl 2): S132-139. doi:10.1086/383275.\u003c/li\u003e\n \u003cli\u003eRice JB, Desai U, Cummings AK, Birnbaum HG, Skornicki M, Persons NB. Burden of diabetic foot ulcers for mediocre and private insurers. \u003cem\u003eDiabetes Care\u003c/em\u003e.\u003cem\u003e\u0026nbsp;\u003c/em\u003e2014;37(3):651-8. doi:10.2337/dc13-2176.\u003c/li\u003e\n \u003cli\u003eMiller JD. Salloum M, Button A, Giovinco NA, Armstrong DG. How can I maintain my patient with diabetes and history of foot ulcer in remission? \u003cem\u003eInt J Low Extrem Wounds\u003c/em\u003e. 2014;13(4):371-377. doi:10.1177/1534734614545874.\u003c/li\u003e\n \u003cli\u003eVeves A, Murray HJ, Boulton AJ. The risk of foot ulceration in diabetic patients with high foot pressure: A prospective study. \u003cem\u003eDiabetologia\u003c/em\u003e.\u003cem\u003e\u0026nbsp;\u003c/em\u003e1992;35(7):660-663.\u003c/li\u003e\n \u003cli\u003eWaaijman R, de Haart M, Arts ML, Wever D, Verlouw AJ, Nollet F, Bus SA. Risk factors for plantar foot ulcer recurrence in neuropathic diabetic patients. \u003cem\u003eDiabetes Care\u003c/em\u003e. 2014;37(6):1697-705. doi:10.2337/dc13-2470.\u0026nbsp;\u003c/li\u003e\n \u003cli\u003eBus SA, Ulbrecht JS, Cavanagh PR, Pressure relief and load redistribution by custom-made insoles in diabetic patients with neuropathy and foot deformity. \u003cem\u003eClin Biomech\u003c/em\u003e (Bristol, Avon). 2004;19(6):629-38. doi: 10.1016/j.clinbiomech.2004.02.010.\u003cem\u003e\u0026nbsp;\u003c/em\u003e\u003c/li\u003e\n \u003cli\u003eAmerican Podiatric Medical Association. Diabetes by the numbers: South Dakota. https://www.apma.org/files/FileDownloads/DiabetesbytheNumbers_South%20Dakota.pdf. Accessed 11 Nov 2021.\u003c/li\u003e\n \u003cli\u003eMeloni M, Izzo V, Giurato L, Lazaro-Martinez JL, Uccioli L. Prevalence, Clinical Aspects and Outcomes in a Large Cohort of Persons with Diabetic Foot Disease: Comparison between Neuropathic and Ischemic Ulcers. J. Clin. Med. 2020, 9(6), 1780; https://doi.org/10.3390/jcm9061780.\u003c/li\u003e\n \u003cli\u003eLipsky BA, Berendt AR, Cornia PB et al. 2012 Infectious Diseases Society of America clinical practice guideline for the diagnosis and treatment of diabetic foot infections. \u003cem\u003eClin Infect Dis\u003c/em\u003e. 2012;54(12): e132-73. doi:10.1093/cid/cis346.\u003cem\u003e\u0026nbsp;\u003c/em\u003e\u003c/li\u003e\n \u003cli\u003eLavery LA, Armstrong DG, Wunderlich RP, Tredwell J, Boulton AJ. Diabetic foot syndrome: evaluating the prevalence and incidence of foot pathology in Mexican Americans and non-Hispanic whites from a diabetes disease management cohort. \u003cem\u003eDiabetes Care\u003c/em\u003e. 2003;26(5):1435-1438. doi:10.2337/diacare.26.5.1435.\u003cem\u003e\u0026nbsp;\u003c/em\u003e\u003c/li\u003e\n \u003cli\u003eSkrepnek GH, Armstrong DG, Mills JL. Open bypass, and endovascular procedures among diabetic foot ulcer cases in the United States from 2001 to 2010. \u003cem\u003eJ Vasc Surg\u003c/em\u003e. 2014;60(5):1255-1265. doi: 10.1016/j.jvs.2014.04.071.\u003c/li\u003e\n \u003cli\u003e\u0026nbsp;Bus SA, van Deursen RW, Armstrong DG, Lewis JE, Caravaggi CF, Cavanagh PR. Footwear and offloading interventions to prevent and heal foot ulcers and reduce plantar pressure in patients with diabetes: A systematic review. \u003cem\u003eDiabetes Metab Res Rev\u003c/em\u003e. 2016;32(Suppl 1):99-118. doi:10.1002/dmrr.2702.\u003c/li\u003e\n \u003cli\u003e\u0026nbsp;Barth R, Campbell LV, Allen S, Jupp JJ, Chisholm DJ. Intensive education improves knowledge, compliance, and foot problems in type 2 diabetes. \u003cem\u003eDiabet Med\u003c/em\u003e. 1991;8(2):111-7. doi:10.1111/j.1464-5491. 1991.tb01555. x.\u003c/li\u003e\n \u003cli\u003eBorges WJ. The impact of a brief foot care intervention for persona with diabetes. University of\u0026nbsp;Texas Health Science Center at Huston School of Nursing;\u0026nbsp;2004.\u0026nbsp;https://www.researchgate.net/publication/28789862. Accessed 11 Nov 2021.\u003c/li\u003e\n \u003cli\u003eLavery LA, Fontaine J, Kim PJ. Preventing the first or recurrent ulcers. \u003cem\u003eMed Clin North Am.\u0026nbsp;\u003c/em\u003e2013; 97:807-820.\u003c/li\u003e\n \u003cli\u003eBerengueres J, Fritschi M, McClanahan R. A smart pressure-sensitive insole that reminds you to walk correctly: An orthotic-less treatment for over pronation. \u003cem\u003eAnn Int\u003c/em\u003e \u003cem\u003eConf Proc IEEE Eng Med Biol Soc\u003c/em\u003e.\u0026nbsp;2014; 2014:2488-2491.\u0026nbsp;doi:10.1109/EMBC.2014.6944127.\u003c/li\u003e\n \u003cli\u003e\u0026nbsp;Ferber R, Webber T, Everett B, Groenland M. Validation of plantar measurements for a novel in-shoe plantar sensory replacement unit. \u003cem\u003eJ Diabetes Sci Technol\u003c/em\u003e. 2013;7(5):1167-75. doi:10.1177/193229681300700535.\u0026nbsp;\u003c/li\u003e\n \u003cli\u003eFarhad F, Gray LC, Russell AW. A Clinimetric Study of outpatient diabetes consultations: The potential for telemedicine substitution. \u003cem\u003eDiabetes Technol Ther\u003c/em\u003e. 2014;16(1):8-14. doi:10.1089/dia.2013.0213.\u003c/li\u003e\n \u003cli\u003eMbue ND, Wang J, Cron SG, Anderson JA. A multiple behavior self-monitoring intervention for African American Veterans with type 2 diabetes: A feasibility implementation study. \u003cem\u003eJ Natl Black Nurses Assoc\u003c/em\u003e. 2017;28(1):1-8.\u003cem\u003e\u0026nbsp;\u003c/em\u003e\u003c/li\u003e\n \u003cli\u003eBandura A. Self-efficacy: Toward a unifying theory of behavioral change. \u003cem\u003ePsychol Rev\u003c/em\u003e. 1977;84(2):191-215. doi:10.1037//0033-295x.84.2.191.\u003c/li\u003e\n \u003cli\u003eAmerican Diabetes Association. Standards of Medical Care in Diabetes-2017. \u003cem\u003eJ\u0026nbsp;Clin Applied\u003c/em\u003e \u003cem\u003eRes Educ\u003c/em\u003e. 2017;40(1):1-142.\u003c/li\u003e\n \u003cli\u003eNational Institute for Health and Care Excellence. Diabetic foot problems: Prevention\u0026nbsp;and\u0026nbsp;management.\u0026nbsp;2019.\u0026nbsp;https://www.nice.org.uk/guidance/ng19. Accessed 11 Nov 2021.\u003c/li\u003e\n \u003cli\u003eAmputation Prevention Reports-British Columbia-Diabetes. https://www.diabetes.ca/newsroom/search-news/mortality-rate-of-diabetic-foot-disease. Accessed 11 Nov 2021.\u003c/li\u003e\n \u003cli\u003eRegistered Nurse\u0026rsquo; Association of Ontario. Assessment and management of foot ulcers for people with diabetes, second edition-201. https://rnao.ca/sites/rnao ca/files/Assessment_and_Management_of_Foot_Ulcers_for_People_with_Diabetes_Second_Edition1.pdf. Accessed 11 Nov 2021.\u003c/li\u003e\n \u003cli\u003eSharoni SKA, Rahman HA, Minhat HS, Ghazali SS, Ong MHA. A self-efficacy education programme on foot-self-care behavior among older patients with diabetes in a public long-term care institution, Malaysia: A quasi-experimental pilot study. \u003cem\u003eBMJ\u003c/em\u003e. 2017;7: e014393.\u0026nbsp;doi:10.1136/bmjopen-2016-014393.\u003c/li\u003e\n \u003cli\u003eBaylor College of Medicine. Explore research at Baylor College of Medicine. https://www.bcm.edu/research. Accessed 11 Nov 2021.\u003c/li\u003e\n \u003cli\u003eRobles RB, Ortiz LGC, Quirate NHG, Berry DC Aguilera P, Martinez SP. Knowledge and practices of diabetes foot care and risk of developing foot ulcers in Mexico may have implications for patients of Mexican heritage living in the US. \u003cem\u003eDiabetes Edu\u003c/em\u003ec. 2017;43(3):297-303. doi:10.1177/0145721717706417.\u003c/li\u003e\n \u003cli\u003eHasnian S, Sheikh NH. Knowledge and practices regarding foot care in diabetic patients visiting diabetic clinic in Jinnah Hospital, Lahore. \u003cem\u003eJ Pak Med Assoc\u003c/em\u003e. 2009;59(10):687-690.\u003c/li\u003e\n \u003cli\u003eGarcia-Inzunza JA, Valles-Medina AM, Munoz FA, Delgadillo-Ramos G, Compean-Ortiz LG. Validation of the Mexican version of the combined foot care confidence/foot-care behavior scale for diabetes. \u003cem\u003eRev Panam Salud Publica\u003c/em\u003e. 2015;38(1):35-41.\u003c/li\u003e\n \u003cli\u003eSloan HL. Developing and testing of the Foot Care Confidence Scale. \u003cem\u003eJ Nurs Meas\u003c/em\u003e. 2002;10(3):207-218. doi:10.1891/jnum.10.3.207.52564.\u003c/li\u003e\n \u003cli\u003eMini-Mental State Examination (MMSE). https://www.http://www.fammed.usouthal.edu/Guides\u0026amp;JobAids/Geriatric/MMSE.pdf. Accessed 11 Nov 2021.\u003c/li\u003e\n \u003cli\u003eCohen J. \u003cem\u003eStatistical Power Analysis for the Behavioral Sciences\u003c/em\u003e. New York, NY: Routledge;\u0026nbsp;2013.\u003c/li\u003e\n \u003cli\u003eAbbot CA, Chatwin KE, Foden P, et al. Innovative intelligent insole system reduces diabetic foot ulcer: A prospective, randomized, proof-of-concept study. \u003cem\u003eLancet Digit Health\u003c/em\u003e. 2019;1(6): e308-e318. doi:10.1016/S2589-7500(19)30128-1.\u003c/li\u003e\n \u003cli\u003e\u0026nbsp;Sicco AB, Lavery LA, Monteiro-Soares M, et al. IWGDF Guideline on the prevention of foot ulcers in person with diabetes-2019. https://iwgdfguidelines.org/wp-content/uploads/2019/05/02-IWGDF-prevention-guideline-2019.pdf. Accessed 11 Nov 2021.\u003c/li\u003e\n \u003cli\u003eJarl G. Methodological considerations of investigating adherence to using offloading devices among people with diabetes. \u003cem\u003ePatient Prefer Adherence\u003c/em\u003e. 2018; 12:1767-1775. doi:10.2147/PPA.S175738.\u0026nbsp;\u003c/li\u003e\n \u003cli\u003eOori MJ, Mohammadi F, Norouzi K, et al. Conceptual model of medication adherence in older adults with high blood pressure-An integrated review of the literature. \u003cem\u003eCurr Hypertens Rev\u003c/em\u003e. 2019;15(2):85-92. doi:10.2174/1573402114666181022152313.\u003cem\u003e\u0026nbsp;\u003c/em\u003e\u003c/li\u003e\n \u003cli\u003eWaaijman R, Keukenkamp R, Haart M, et al. Adherence to wearing prescription custom-made footwear in patients with diabetes at high risk for plantar foot ulceration. \u003cem\u003eDiabetes Care\u003c/em\u003e. 2013;36(6):1613-8. doi:10.2337/dc12-1330.\u003cem\u003e\u0026nbsp;\u003c/em\u003e\u003c/li\u003e\n \u003cli\u003eKnowles EA, Boulton AJ. Do people with diabetes wear their prescribed footwear? \u003cem\u003eDiabet Med\u003c/em\u003e. 1996;13(12):1064-1068. doi:10.1002/(SICI)1096-9136(199612)13:12\u0026lt;1064: AID-DIA253\u0026gt;3.0.CO;2-#.\u003c/li\u003e\n \u003cli\u003eMcCabe CJ, Stevenson RC, Dolan AM. Evaluation of a diabetic programme. \u003cem\u003eDiabet Med\u003c/em\u003e.\u003cem\u003e\u0026nbsp;\u003c/em\u003e1998;15(1):80-84.\u003c/li\u003e\n \u003cli\u003eNeibauer G. The diabetic Foot-2017. https://alpinefoot.com/. Accessed 11 Nov 2021.\u003c/li\u003e\n \u003cli\u003eAmerican Diabetes Association. Standards of Medical Care in Diabetes-2020. Clinical Diabetes, 2020; 38(1): 10-38. https://doi.org/10.2337/cd20-as01.\u003c/li\u003e\n \u003cli\u003eMineka S, Watson D, Clark LA. Comorbidity of anxiety and unipolar mood disorder. \u003cem\u003eAnnu Rev Psychol\u003c/em\u003e. 1998; 49:377-412. doi: 10.1146/annurev.psych.49.1.377.\u0026nbsp;\u003c/li\u003e\n \u003cli\u003eAseri ZA, Suriya MO, Hassan HA, et al. Reliability and validity of the Hospital Anxiety and Depression Scale in an emergency department in Saudi Arabia: A cross-sectional observational study. \u003cem\u003eBMC Emerg Med\u003c/em\u003e. 2015; 15:28. doi:10.1186/s12873-015-0051-4.\u0026nbsp;\u003c/li\u003e\n \u003cli\u003eZimet GD, Dahlem NW, Zimet SG, Farley GK. The Multidimensional Scale of Perceived Social Support\u003cem\u003e. J Pers Assess\u003c/em\u003e. 1988; 52:30-41. doi:10.1207/s15327752jpa5201_2.\u003c/li\u003e\n \u003cli\u003eWongpakaran T, Wongpakaran N, Ruktrakul R. Reliability, and validity of the Multidimensional Scale of Perceived Social Support (MSPSS): Thai version. \u003cem\u003eClin Pract Epidemiol Ment Health\u003c/em\u003e. 2011; 7:161-166. doi:10.2174/1745017901107010161.\u0026nbsp;\u003c/li\u003e\n \u003cli\u003eCenters for Disease Control and Prevention. National Diabetes Statistics Report, 2020. https://www.cdc.gov/diabetes/library/features/diabetes-stat-report.html. Accessed 9 July 2021.\u003c/li\u003e\n \u003cli\u003eAlfonso AR, Smita Rao PT, Everett B, Chiu ES. Novel pressure-sensing smart insole system used for the prevention of pressure ulceration in the insensate foot\u003cem\u003e. Plast Reconstr Surg Glob Open\u003c/em\u003e.\u003cem\u003e\u0026nbsp;\u003c/em\u003e2017;5(12): e1568. doi:10.1097/GOX.0000000000001568.\u0026nbsp;\u003c/li\u003e\n \u003cli\u003evan Netten JJ, Raspovic A, Lavery LA, et al. Prevention of foot ulcers in the at-risk patient with diabetes: A systematic review. \u003cem\u003eDiabetes Metab Res Rev\u003c/em\u003e. 2020;36 Suppl 1: e3270. doi:10.1002/dmrr.3270.\u003c/li\u003e\n \u003cli\u003e\u0026nbsp;Shin L, Armstrong D, Sanders LJ. Foot Ulcers: John\u0026rsquo;s Hopkins Diabetes Care 2020. https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_Diabetes_Guide/547054/all/Foot_Ulcers. Accessed 12 July 2021.\u003c/li\u003e\n \u003cli\u003e\u0026nbsp;Diabetic Foot Fact. The global burden of diabetes and foot complications: the facts. https://www.d-foot.org/diabetic-foot/diabetic-foot-facts. Accessed 11 Nov 2021.\u003c/li\u003e\n\u003c/ol\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":false,"hideJournal":true,"highlight":"","institution":"","isAcceptedByJournal":false,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":true,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true},"keywords":"Diabetic footwear, Diabetic foot ulcers, Adherence, Foot self-care education, Randomized control trial","lastPublishedDoi":"10.21203/rs.3.rs-1099111/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-1099111/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003ch2\u003eBackground\u003c/h2\u003e \u003cp\u003eUnprotected plantar pressure contributes to the development of diabetic foot ulcers (DFU) in people with diabetes and loss of plantar sensation. Recently, smart footwear device is proposed to empower patients at risk in avoiding harmful weight-bearing physical activities such as prolonged standing which may lead to local plantar ischemia and ultimately a DFU. However, there is little progress in the education of at-risk to be engaged in daily using of these smart footwear devices as well as adherence to diabetic footwear. The aim of this study is to examine whether an integration of smart insoles with an alert (smart watch) and foot self-care education may sustain adherence to prescribed footwear and change patients\u0026rsquo; behavior to avoid harmful physical activities such as prolonged standing posture.\u003c/p\u003e\u003ch2\u003eMethods/design\u003c/h2\u003e \u003cp\u003e: The trial is designed as a three-arm randomized controlled intervention study. Adults with peripheral neuropathy will be recruited. Seventy-two participants will be randomized into three groups: 1) smart insoles + foot self-care education; 2) smart insoles; and 3) usual-care controls with no smart insoles or education. Primary outcomes will be adherence to diabetic footwear and offloading after 6 months. Secondary outcomes are foot self-care knowledge and self-efficacy, reduction of sustained plantar pressure, incident of DFU, acceptability, and perception of benefits of intervention. Data collection will be obtained at baseline, bi-weekly in first month, two, four and six months. Latent growth curve mediation model will be used to test the effects of the combined smart insole and foot self-care education on improving adherence to footwear at every two months until six months, in which time points will be used as repeated measures. It allows for testing differences between groups in patterns over time as well as at specific time points. The Institutional Review Board at the Texas Woman\u0026rsquo;s University (Reference No. has approved the study protocol FY2021-344).\u003c/p\u003e\u003ch2\u003eDiscussion\u003c/h2\u003e \u003cp\u003eThis clinical trial will provide information on the importance of foot self-care education and the use of technology (smart insole plus smart watch) in reducing the incidence of foot ulcers and increase adherence to diabetic footwear. This research could also lead to critical mechanistic discoveries and, subsequently, major advancements in prevention of DFU and limb amputation. This impact would have high potential for translation to routine clinical diabetes care.\u003c/p\u003e\u003ch2\u003eTrial registration\u003c/h2\u003e \u003cp\u003e: United States Clinical Trial Registry NCT05074849. Registered on 29 September 2021.\u003c/p\u003e","manuscriptTitle":"Benefits of Insoles with Real-Time Alert and Foot Self-Care Education in Improving Offloading and Adherence to Prescribed Footwear in Patients with Diabetes Mellitus: Study Protocol for a Single-Blinded Randomized Clinical Trial","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2022-05-06 15:36:19","doi":"10.21203/rs.3.rs-1099111/v1","editorialEvents":[{"type":"communityComments","content":0}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"c019462a-02bc-420d-9e81-a89e8009884e","owner":[],"postedDate":"May 6th, 2022","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"posted","subjectAreas":[],"tags":[],"updatedAt":"2022-08-04T03:00:44+00:00","versionOfRecord":[],"versionCreatedAt":"2022-05-06 15:36:19","video":"","vorDoi":"","vorDoiUrl":"","workflowStages":[]},"version":"v1","identity":"rs-1099111","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-1099111","identity":"rs-1099111","version":["v1"]},"buildId":"cBFmMYwuxLRRLfASyISRj","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}